{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:14:16Z","timestamp":1793272456612,"version":"4.5.0"},"reference-count":461,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02729-x","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T05:01:45Z","timestamp":1781586105000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Non-receptor tyrosine kinase signaling pathways and therapeutic implications"],"prefix":"10.1038","volume":"11","author":[{"given":"MD Anwar","family":"Hossain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila","family":"Marques Cuoco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snigdha Hemant","family":"Sodaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris","family":"Beci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Belkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"2729_CR1","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.3390\/cancers16152754","volume":"16","author":"AM Eshaq","year":"2024","unstructured":"Eshaq, A. M. et al. Non-receptor tyrosine kinases: their structure and mechanistic role in tumor progression and resistance. Cancers 16, 2754 (2024).","journal-title":"Cancers"},{"key":"2729_CR2","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.82345","volume":"12","author":"A Li","year":"2023","unstructured":"Li, A., Voleti, R., Lee, M., Gagoski, D. & Shah, N. H. High-throughput profiling of sequence recognition by tyrosine kinases and SH2 domains using bacterial peptide display. eLife 12, e82345 (2023).","journal-title":"eLife"},{"key":"2729_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.str.2024.10.020","volume":"33","author":"C Soteriou","year":"2025","unstructured":"Soteriou, C. et al. Two cooperative lipid binding sites within the pleckstrin homology domain are necessary for AKT binding and stabilization to the plasma membrane. Structure 33, 181\u2013195 (2025).","journal-title":"Structure"},{"key":"2729_CR4","doi-asserted-by":"publisher","first-page":"29700","DOI":"10.1074\/jbc.M313185200","volume":"297","author":"E Hong","year":"2004","unstructured":"Hong, E., Shin, J., Kim, H. I., Lee, S. T. & Lee, W. Solution structure and backbone dynamics of the non-receptor protein-tyrosine kinase-6 Src homology 2 domain. J. Biol. Chem. 297, 29700\u201329708 (2004).","journal-title":"J. Biol. Chem."},{"key":"2729_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05884-z","volume":"14","author":"SU Seo","year":"2023","unstructured":"Seo, S. U., Woo, S. M. & Kwon, T. K. Cathepsin K inhibition induces raptor destabilization and mitochondrial dysfunction via Syk\/SHP2\/Src\/OTUB1 axis-mediated signaling. Cell Death Dis. 14, 366 (2023).","journal-title":"Cell Death Dis."},{"key":"2729_CR6","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41392-022-01268-5","volume":"8","author":"C Zhou","year":"2023","unstructured":"Zhou, C. et al. B-lymphoid tyrosine kinase-mediated FAM83A phosphorylation elevates pancreatic tumorigenesis through interacting with \u03b2-catenin. Signal Transduct. Target. Ther. 8, 66 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2729_CR7","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.96085.3","volume":"13","author":"S Guillet","year":"2024","unstructured":"Guillet, S. et al. ACK1 and BRK non-receptor tyrosine kinase deficiencies are associated with familial systemic lupus and involved in efferocytosis. eLife 13, RP96085 (2024).","journal-title":"eLife"},{"key":"2729_CR8","first-page":"994","volume":"127","author":"S Jones","year":"2014","unstructured":"Jones, S., Cunningham, D. L., Rappoport, J. Z. & Heath, J. K. The non-receptor tyrosine kinase Ack1 regulates the fate of activated EGFR by inducing trafficking to the p62\/NBR1 pre-autophagosome. J. Cell Sci. 127, 994\u20131006 (2014).","journal-title":"J. Cell Sci."},{"key":"2729_CR9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41420-022-00927-4","volume":"8","author":"Z Yin","year":"2022","unstructured":"Yin, Z. et al. Regulation of the Tec family of non-receptor tyrosine kinases in cardiovascular disease. Cell Death Discov. 8, 119 (2022).","journal-title":"Cell Death Discov."},{"key":"2729_CR10","doi-asserted-by":"publisher","first-page":"1163137","DOI":"10.3389\/fmed.2023.1163137","volume":"10","author":"R Kaddoura","year":"2023","unstructured":"Kaddoura, R., Dabdoob, W. A., Ahmed, K. & Yassin, M. A. A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia. Front. Med. 10, 1163137 (2023).","journal-title":"Front. Med."},{"key":"2729_CR11","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3389\/fonc.2019.00603","volume":"9","author":"V Garc\u00eda-Guti\u00e9rrez","year":"2019","unstructured":"Garc\u00eda-Guti\u00e9rrez, V. & Hern\u00e1ndez-Boluda, J. C. Tyrosine kinase inhibitors available for chronic myeloid leukemia: efficacy and safety. Front. Oncol. 9, 603 (2019).","journal-title":"Front. Oncol."},{"key":"2729_CR12","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.nbd.2004.06.007","volume":"17","author":"AR Alvarez","year":"2004","unstructured":"Alvarez, A. R., Sandoval, P. C., Leal, N. R., Castro, P. U. & Kosik, K. S. Activation of the neuronal c-Abl tyrosine kinase by amyloid-\u03b2-peptide and reactive oxygen species. Neurobiol. Dis. 17, 326\u2013336 (2004).","journal-title":"Neurobiol. Dis."},{"key":"2729_CR13","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s40268-019-0266-z","volume":"19","author":"AJ Fowler","year":"2019","unstructured":"Fowler, A. J. et al. Multikinase Abl\/DDR\/Src inhibition produces optimal effects for tyrosine kinase inhibition in neurodegeneration. Drugs RD 19, 149\u2013166 (2019).","journal-title":"Drugs RD"},{"key":"2729_CR14","doi-asserted-by":"publisher","first-page":"749001","DOI":"10.3389\/fnsyn.2021.749001","volume":"13","author":"B de Pins","year":"2021","unstructured":"de Pins, B., Mendes, T., Giralt, A. & Girault, J. A. The non-receptor tyrosine kinase Pyk2 in brain function and neurological and psychiatric diseases. Front. Synaptic Neurosci. 13, 749001 (2021).","journal-title":"Front. Synaptic Neurosci."},{"key":"2729_CR15","doi-asserted-by":"publisher","first-page":"7877","DOI":"10.1073\/pnas.1508223112","volume":"112","author":"T Hunter","year":"2015","unstructured":"Hunter, T. Discovering the first tyrosine kinase. Proc. Natl. Acad. Sci. 112, 7877\u20137882 (2015).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"2729_CR16","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.3390\/cancers12061448","volume":"12","author":"S Martellucci","year":"2020","unstructured":"Martellucci, S. et al. Src family kinases as therapeutic targets in advanced solid tumors: what we have learned so far. Cancers 12, 1448 (2020).","journal-title":"Cancers"},{"key":"2729_CR17","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.chembiol.2012.01.020","volume":"19","author":"S Hellwig","year":"2012","unstructured":"Hellwig, S. et al. Small molecule inhibitors of the c-Fes protein-tyrosine kinase. Chem. Biol. 19, 529\u2013540 (2012).","journal-title":"Chem. Biol."},{"key":"2729_CR18","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3389\/fonc.2018.00287","volume":"8","author":"E Bousoik","year":"2018","unstructured":"Bousoik, E. & Montazeri Aliabadi, H. \u201cDo We Know Jack\u201d About JAK? A closer look at JAK\/STAT signaling pathway. Front. Oncol. 8, 287 (2018).","journal-title":"Front. Oncol."},{"key":"2729_CR19","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/0092-8674(89)90407-8","volume":"58","author":"FB Gertler","year":"1989","unstructured":"Gertler, F. B., Bennett, R. L., Clark, M. J. & Hoffmann, F. M. Drosophila abl tyrosine kinase in embryonic CNS axons: a role in axonogenesis is revealed through dosage-sensitive interactions with disabled. Cell 58, 103\u2013113 (1989).","journal-title":"Cell"},{"key":"2729_CR20","first-page":"76","volume":"11","author":"K Mehta","year":"2024","unstructured":"Mehta, K. et al. Targeting RTKs\/nRTKs as promising therapeutic strategies for the treatment of triple-negative breast cancer: evidence from clinical trials. Mil. Med. Res. 11, 76 (2024).","journal-title":"Mil. Med. Res."},{"key":"2729_CR21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jaad.2023.04.027","volume":"89","author":"PA Jimenez","year":"2023","unstructured":"Jimenez, P. A. et al. Oral spleen tyrosine kinase\/Janus Kinase inhibitor gusacitinib for the treatment of chronic hand eczema: results of a randomized phase 2 study. J. Am. Acad. Dermatol. 89, 235\u2013242 (2023).","journal-title":"J. Am. Acad. Dermatol."},{"key":"2729_CR22","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1002\/art.42519","volume":"75","author":"P Mease","year":"2023","unstructured":"Mease, P. et al. Efficacy and safety of the TYK2\/JAK1 inhibitor brepocitinib for active psoriatic arthritis: a phase IIb randomized controlled trial. Arthritis Rheumatol. 75, 1370\u20131380 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"2729_CR23","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.3390\/molecules26144250","volume":"26","author":"XJ Pang","year":"2021","unstructured":"Pang, X. J. et al. Drug Discovery targeting focal adhesion kinase (FAK) as a promising cancer therapy. Molecules 26, 4250 (2021).","journal-title":"Molecules"},{"key":"2729_CR24","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1158\/1078-0432.CCR-19-2777","volume":"26","author":"MR Yun","year":"2020","unstructured":"Yun, M. R. et al. Repotrectinib exhibits potent antitumor activity in treatment-na\u00efve and solvent-front\u2013mutant ROS1-rearranged non\u2013small cell lung cancer. Clin. Cancer Res. 26, 3287\u20133295 (2020).","journal-title":"Clin. Cancer Res."},{"key":"2729_CR25","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.clim.2008.02.006","volume":"127","author":"S Blake","year":"2008","unstructured":"Blake, S., Hughes, T. P., Mayrhofer, G. & Lyons, A. B. The Src\/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro. Clin. Immunol. 127, 330\u2013339 (2008).","journal-title":"Clin. Immunol."},{"key":"2729_CR26","first-page":"1","volume":"8","author":"C Xue","year":"2023","unstructured":"Xue, C. et al. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduct. Target. Ther. 8, 1\u201324 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2729_CR27","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aav3810","volume":"12","author":"A Kwon","year":"2019","unstructured":"Kwon, A. et al. Tracing the origin and evolution of pseudokinases across the tree of life. Sci. Signal. 12, eaav3810 (2019).","journal-title":"Sci. Signal."},{"key":"2729_CR28","doi-asserted-by":"publisher","first-page":"900","DOI":"10.3390\/cells12060900","volume":"12","author":"Y Kan","year":"2023","unstructured":"Kan, Y., Paung, Y., Seeliger, M. A. & Miller, W. T. Domain architecture of the nonreceptor tyrosine kinase Ack1. Cells 12, 900 (2023).","journal-title":"Cells"},{"key":"2729_CR29","doi-asserted-by":"publisher","first-page":"575220","DOI":"10.3389\/fendo.2020.575220","volume":"11","author":"R Jaber Chehayeb","year":"2020","unstructured":"Jaber Chehayeb, R. & Boggon, T. J. SH2 domain binding: diverse FLVRs of partnership. Front. Endocrinol. 11, 575220 (2020).","journal-title":"Front. Endocrinol."},{"key":"2729_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50812-0","volume":"15","author":"J Gizzio","year":"2024","unstructured":"Gizzio, J., Thakur, A., Haldane, A., Post, C. B. & Levy, R. M. Evolutionary sequence and structural basis for the distinct conformational landscapes of Tyr and Ser\/Thr kinases. Nat. Commun. 15, 6545 (2024).","journal-title":"Nat. Commun."},{"key":"2729_CR31","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.3892\/ijo.2015.2910","volume":"46","author":"B Xie","year":"2015","unstructured":"Xie, B. et al. ACK1 promotes hepatocellular carcinoma progression via downregulating WWOX and activating AKT signaling. Int. J. Oncol. 46, 2057\u20132066 (2015).","journal-title":"Int. J. Oncol."},{"key":"2729_CR32","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.prp.2009.07.002","volume":"205","author":"T Ozkal","year":"2009","unstructured":"Ozkal, T. et al. Focal adhesion kinase (FAK) expression in normal and neoplastic lymphoid tissues. Pathol. Res. Pract. 205, 781\u2013788 (2009).","journal-title":"Pathol. Res. Pract."},{"key":"2729_CR33","doi-asserted-by":"publisher","first-page":"14865","DOI":"10.1073\/pnas.251249298","volume":"98","author":"Y Wang","year":"2001","unstructured":"Wang, Y., Miller, A. L., Mooseker, M. S. & Koleske, A. J. The Abl-related gene (Arg) nonreceptor tyrosine kinase uses two F-actin-binding domains to bundle F-actin. Proc. Natl. Acad. Sci. 98, 14865\u201314870 (2001).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"2729_CR34","doi-asserted-by":"publisher","first-page":"4917","DOI":"10.1038\/s41388-022-02487-4","volume":"41","author":"SG Pelaz","year":"2022","unstructured":"Pelaz, S. G. & Tabernero, A. Src: coordinating metabolism in cancer. Oncogene 41, 4917\u20134928 (2022).","journal-title":"Oncogene"},{"key":"2729_CR35","doi-asserted-by":"publisher","first-page":"9796","DOI":"10.1073\/pnas.0603714103","volume":"103","author":"ML Galisteo","year":"2006","unstructured":"Galisteo, M. L., Yang, Y., Ure\u00f1a, J. & Schlessinger, J. Activation of the nonreceptor protein tyrosine kinase Ack by multiple extracellular stimuli. Proc. Natl. Acad. Sci. 103, 9796\u20139801 (2006).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"2729_CR36","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/nsmb.2348","volume":"19","author":"RM Bandaranayake","year":"2012","unstructured":"Bandaranayake, R. M. et al. Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. Nat. Struct. Mol. Biol. 19, 754\u2013759 (2012).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2729_CR37","doi-asserted-by":"publisher","first-page":"S713","DOI":"10.1093\/ecco-jcc\/jjz206","volume":"14","author":"A Garrido-Trigo","year":"2020","unstructured":"Garrido-Trigo, A. & Salas, A. Molecular structure and function of Janus kinases: implications for the development of inhibitors. J. Crohns Colitis 14, S713\u2013S724 (2020).","journal-title":"J. Crohns Colitis"},{"key":"2729_CR38","doi-asserted-by":"publisher","first-page":"392","DOI":"10.31083\/j.fbl2911392","volume":"29","author":"K Katoh","year":"2024","unstructured":"Katoh, K. Signal transduction mechanisms of focal adhesions: Src and FAK-mediated cell response. Front. Biosci. 29, 392 (2024).","journal-title":"Front. Biosci."},{"key":"2729_CR39","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/j.str.2024.09.024","volume":"32","author":"WJ Bradshaw","year":"2024","unstructured":"Bradshaw, W. J., Harris, G., Gileadi, O. & Katis, V. L. The mechanism of allosteric activation of SYK kinase derived from multiple phospho-ITAM-bound structures. Structure 32, 2337\u20132351 (2024).","journal-title":"Structure"},{"key":"2729_CR40","doi-asserted-by":"publisher","first-page":"650888","DOI":"10.3389\/fphys.2021.650888","volume":"12","author":"WH Yiu","year":"2021","unstructured":"Yiu, W. H. et al. Spleen tyrosine kinase inhibition ameliorates tubular inflammation in IgA nephropathy. Front. Physiol. 12, 650888 (2021).","journal-title":"Front. Physiol."},{"key":"2729_CR41","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1128\/MCB.00904-08","volume":"29","author":"VA McPherson","year":"2009","unstructured":"McPherson, V. A. et al. Contributions of F-bar and SH2 domains of FES protein tyrosine kinase for coupling to the Fc\u025bRI pathway in mast cells, molecular and cellular biology. Mol. Cell. Biol. 29, 389\u2013401 (2009).","journal-title":"Mol. Cell. Biol."},{"key":"2729_CR42","doi-asserted-by":"publisher","first-page":"1148352","DOI":"10.3389\/fcell.2023.1148352","volume":"11","author":"G Sun","year":"2023","unstructured":"Sun, G. & Ayrapetov, M. K. Dissection of the catalytic and regulatory structure-function relationships of Csk protein tyrosine kinase. Front. Cell Dev. Biol. 11, 1148352 (2023).","journal-title":"Front. Cell Dev. Biol."},{"key":"2729_CR43","doi-asserted-by":"publisher","first-page":"5582","DOI":"10.1038\/onc.2013.277","volume":"32","author":"IA Ivanova","year":"2013","unstructured":"Ivanova, I. A. et al. FER kinase promotes breast cancer metastasis by regulating \u03b16- and \u03b21-integrin-dependent cell adhesion and anoikis resistance. Oncogene 32, 5582\u20135592 (2013).","journal-title":"Oncogene"},{"key":"2729_CR44","doi-asserted-by":"publisher","first-page":"7968","DOI":"10.1073\/pnas.1105369108","volume":"108","author":"C Guo","year":"2011","unstructured":"Guo, C. & Stark, G. R. FER tyrosine kinase (FER) overexpression mediates resistance to quinacrine through EGF-dependent activation of NF-\u03baB. Proc. Natl. Acad. Sci. 108, 7968\u20137973 (2011).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"2729_CR45","doi-asserted-by":"publisher","first-page":"e87684","DOI":"10.1371\/journal.pone.0087684","volume":"9","author":"S Miah","year":"2014","unstructured":"Miah, S. et al. BRK Targets Dok1 for ubiquitin-mediated proteasomal degradation to promote cell proliferation and migration. PLoS ONE 9, e87684 (2014).","journal-title":"PLoS ONE"},{"key":"2729_CR46","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaw3113","volume":"5","author":"S Miah","year":"2019","unstructured":"Miah, S. et al. BRK phosphorylates SMAD4 for proteasomal degradation and inhibits tumor suppressor FRK to control SNAIL, SLUG, and metastatic potential. Sci. Adv. 5, eaaw3113 (2019).","journal-title":"Sci. Adv."},{"key":"2729_CR47","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.7150\/thno.49716","volume":"11","author":"HL Ang","year":"2021","unstructured":"Ang, H. L. et al. Putting the BRK on breast cancer: from molecular target to therapeutics. Theranostics 11, 1115\u20131128 (2021).","journal-title":"Theranostics"},{"key":"2729_CR48","doi-asserted-by":"publisher","first-page":"bqab152","DOI":"10.1210\/endocr\/bqab152","volume":"162","author":"BF Brian","year":"2021","unstructured":"Brian, B. F. & Freedman, T. S. The Src-family Kinase Lyn in immunoreceptor signaling. Endocrinology 162, bqab152 (2021).","journal-title":"Endocrinology"},{"key":"2729_CR49","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1128\/MCB.19.3.1871","volume":"19","author":"AJ Waskiewicz","year":"1999","unstructured":"Waskiewicz, A. J. et al. Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo. Mol. Cell. Biol. 19, 1871\u20131880 (1999).","journal-title":"Mol. Cell. Biol."},{"key":"2729_CR50","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1093\/neuonc\/noac179","volume":"25","author":"A Kosti","year":"2022","unstructured":"Kosti, A. et al. ELF4 is a critical component of a miRNA-transcription factor network and is a bridge regulator of glioblastoma receptor signaling and lipid dynamics. Neuro Oncol. 25, 459 (2022).","journal-title":"Neuro Oncol."},{"key":"2729_CR51","first-page":"25","volume":"21","author":"JQ Wang","year":"2022","unstructured":"Wang, J. Q., Derges, J. D., Bodepudi, A., Pokala, N. & Mao, L. M. Roles of non-receptor tyrosine kinases in pathogenesis and treatment of depression. IMR Press 21, 25 (2022).","journal-title":"IMR Press"},{"key":"2729_CR52","doi-asserted-by":"publisher","first-page":"6211","DOI":"10.3390\/ijms22126211","volume":"22","author":"P Montero","year":"2021","unstructured":"Montero, P., Milara, J., Roger, I. & Cortijo, J. Role of JAK\/STAT in interstitial lung diseases; molecular and cellular mechanisms. Int. J. Mol. Sci. 22, 6211 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"2729_CR53","doi-asserted-by":"publisher","first-page":"1110765","DOI":"10.3389\/fbioe.2023.1110765","volume":"11","author":"Q Hu","year":"2023","unstructured":"Hu, Q. et al. JAK\/STAT pathway: extracellular signals, diseases, immunity, and therapeutic regimens. Front. Bioeng. Biotechnol. 11, 1110765 (2023).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"2729_CR54","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.3390\/cancers11122002","volume":"11","author":"KL Owen","year":"2019","unstructured":"Owen, K. L., Brockwell, N. K. & Parker, B. S. JAK-STAT signaling: a double-edged sword of immune regulation and cancer progression. Cancers 11, 2002 (2019).","journal-title":"Cancers"},{"key":"2729_CR55","doi-asserted-by":"publisher","first-page":"e251","DOI":"10.1038\/oncsis.2016.54","volume":"5","author":"R Manek","year":"2016","unstructured":"Manek, R. et al. Targeting Src in endometriosis-associated ovarian cancer. Oncogenesis 5, e251\u2013e251 (2016).","journal-title":"Oncogenesis"},{"key":"2729_CR56","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3390\/biom5010263","volume":"5","author":"N Filippova","year":"2015","unstructured":"Filippova, N., Yang, X. & Nabors, L. B. Growth factor dependent regulation of centrosome function and genomic instability by HuR. Biomolecules 5, 263\u2013281 (2015).","journal-title":"Biomolecules"},{"key":"2729_CR57","doi-asserted-by":"publisher","first-page":"114297","DOI":"10.1016\/j.celrep.2024.114297","volume":"43","author":"MZ Akhter","year":"2024","unstructured":"Akhter, M. Z. et al. FAK regulates tension transmission to the nucleus and endothelial transcriptome independent of kinase activity. Cell Rep. 43, 114297 (2024).","journal-title":"Cell Rep."},{"key":"2729_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01298-3","volume":"22","author":"R Paul","year":"2020","unstructured":"Paul, R. et al. FAK activates AKT-mTOR signaling to promote the growth and progression of MMTV-Wnt1-driven basal-like mammary tumors. Breast Cancer Res. 22, 59 (2020).","journal-title":"Breast Cancer Res."},{"key":"2729_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-024-03383-5","volume":"24","author":"W Zhu","year":"2024","unstructured":"Zhu, W. et al. SULF1 regulates malignant progression of colorectal cancer by modulating ARSH via FAK\/PI3K\/AKT\/mTOR signaling. Cancer Cell Int. 24, 201 (2024).","journal-title":"Cancer Cell Int."},{"key":"2729_CR60","doi-asserted-by":"publisher","first-page":"16636","DOI":"10.1074\/jbc.M112.357640","volume":"287","author":"B Katkere","year":"2012","unstructured":"Katkere, B., Rosa, S. & Drake, J. R. The Syk-binding Ubiquitin Ligase c-Cbl mediates signaling-dependent B cell receptor ubiquitination and B cell receptor-mediated antigen processing and presentation. J. Biol. Chem. 287, 16636 (2012).","journal-title":"J. Biol. Chem."},{"key":"2729_CR61","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.pharmthera.2019.05.008","volume":"201","author":"S Solouki","year":"2019","unstructured":"Solouki, S., August, A. & Huang, W. Non-receptor tyrosine kinase signaling in autoimmunity and therapeutic implications. Pharmacol. Ther. 201, 39 (2019).","journal-title":"Pharmacol. Ther."},{"key":"2729_CR62","first-page":"1","volume":"9","author":"J Su","year":"2024","unstructured":"Su, J. et al. Cell\u2013cell communication: new insights and clinical implications. Signal Transduct. Target. Ther. 9, 1\u201352 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2729_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-00294-0","volume":"8","author":"SB Mkaddem","year":"2017","unstructured":"Mkaddem, S. B. et al. Lyn and Fyn function as molecular switches that control immunoreceptors to direct homeostasis or inflammation. Nat. Commun. 8, 1\u201313 (2017).","journal-title":"Nat. Commun."},{"key":"2729_CR64","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13045-017-0512-1","volume":"10","author":"D Liu","year":"2017","unstructured":"Liu, D. & Mamorska-Dyga, A. Syk inhibitors in clinical development for hematological malignancies. J. Hematol. Oncol. 10, 145 (2017).","journal-title":"J. Hematol. Oncol."},{"key":"2729_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28373-x","volume":"13","author":"MA Alfonzo-M\u00e9ndez","year":"2022","unstructured":"Alfonzo-M\u00e9ndez, M. A., Sochacki, K. A., Strub, M. P. & Taraska, J. W. Dual clathrin and integrin signaling systems regulate growth factor receptor activation. Nat. Commun. 13, 905 (2022).","journal-title":"Nat. Commun."},{"key":"2729_CR66","doi-asserted-by":"publisher","first-page":"ar138","DOI":"10.1091\/mbc.E24-05-0226","volume":"35","author":"MA Alfonzo-M\u00e9ndez","year":"2024","unstructured":"Alfonzo-M\u00e9ndez, M. A., Strub, M. P. & Taraska, J. W. Spatial and signaling overlap of growth factor receptor systems at clathrin-coated sites. Mol. Biol. Cell. 35, ar138 (2024).","journal-title":"Mol. Biol. Cell."},{"key":"2729_CR67","first-page":"1","volume":"9","author":"Y Tao","year":"2024","unstructured":"Tao, Y., Zhang, Q., Wang, H., Yang, X. & Mu, H. Alternative splicing and related RNA binding proteins in human health and disease. Signal Transduct. Target. Ther. 9, 1\u201333 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2729_CR68","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1091\/mbc.10.11.3909","volume":"10","author":"AM Hartmann","year":"1999","unstructured":"Hartmann, A. M., Nayler, O., Schwaiger, F. W., Obermeier, A. & Stamm, S. The interaction and colocalization of Sam68 with the splicing-associated factor YT521-B in nuclear dots is regulated by the Src family kinase p59fyn. Mol. Biol. Cell 10, 3909\u20133926 (1999).","journal-title":"Mol. Biol. Cell"},{"key":"2729_CR69","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.bbrc.2016.03.108","volume":"473","author":"S Mai","year":"2016","unstructured":"Mai, S. et al. Functional interaction between nonreceptor tyrosine kinase c-Abl and SR-rich protein RBM39. Biochem. Biophys. Res. Commun. 473, 355\u2013360 (2016).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2729_CR70","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1321185","volume":"6","author":"C Penafuerte","year":"2017","unstructured":"Penafuerte, C. et al. Downregulation of PTP1B and TC-PTP phosphatases potentiate dendritic cell-based immunotherapy through IL-12\/IFN\u03b3 signaling. OncoImmunology 6, e1321185 (2017).","journal-title":"OncoImmunology"},{"key":"2729_CR71","first-page":"1","volume":"9","author":"C Tomuleasa","year":"2024","unstructured":"Tomuleasa, C. et al. Therapeutic advances of targeting receptor tyrosine kinases in cancer. Signal Transduct. Target. Ther. 9, 1\u201351 (2024).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2729_CR72","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.bbrc.2004.09.171","volume":"324","author":"R Roskoski","year":"2004","unstructured":"Roskoski, R. Src protein\u2013tyrosine kinase structure and regulation. Biochem. Biophys. Res. Commun. 324, 1155\u20131164 (2004).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2729_CR73","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1042\/BJ20141492","volume":"468","author":"S Lorenz","year":"2015","unstructured":"Lorenz, S., Deng, P., Hantschel, O., Superti-Furga, G. & Kuriyan, J. Crystal structure of an SH2-kinase construct of c-Abl and effect of the SH2 domain on kinase activity. Biochem. J. 468, 283\u2013291 (2015).","journal-title":"Biochem. J."},{"key":"2729_CR74","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s10585-007-9065-y","volume":"24","author":"S Hiscox","year":"2007","unstructured":"Hiscox, S., Jordan, N. J., Morgan, L., Green, T. P. & Nicholson, R. I. Src kinase promotes adhesion-independent activation of FAK and enhances cellular migration in tamoxifen-resistant breast cancer cells. Clin. Exp. Metastasis 24, 157\u2013167 (2007).","journal-title":"Clin. Exp. Metastasis"},{"key":"2729_CR75","doi-asserted-by":"publisher","first-page":"8113","DOI":"10.1128\/MCB.24.18.8113-8133.2004","volume":"24","author":"MA Westhoff","year":"2004","unstructured":"Westhoff, M. A., Serrels, B., Fincham, V. J., Frame, M. C. & Carragher, N. O. Src-mediated phosphorylation of focal adhesion kinase couples actin and adhesion dynamics to survival signaling. Mol. Cell. Biol. 24, 8113 (2004).","journal-title":"Mol. Cell. Biol."},{"key":"2729_CR76","doi-asserted-by":"publisher","first-page":"1078180","DOI":"10.3389\/fcell.2022.1078180","volume":"10","author":"A Fortner","year":"2022","unstructured":"Fortner, A., Chera, A., Tanca, A. & Bucur, O. Apoptosis regulation by the tyrosine-protein kinase CSK. Front. Cell Dev. Biol. 10, 1078180 (2022).","journal-title":"Front. Cell Dev. Biol."},{"key":"2729_CR77","doi-asserted-by":"publisher","first-page":"a026104","DOI":"10.1101\/cshperspect.a026104","volume":"6","author":"J Chen","year":"2016","unstructured":"Chen, J. The cell-cycle arrest and apoptotic functions of p53 in tumor initiation and progression. Cold Spring Harb. Perspect. Med. 6, a026104 (2016).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"2729_CR78","first-page":"1","volume":"6","author":"K Shah","year":"2021","unstructured":"Shah, K., Al-Haidari, A., Sun, J. & Kazi, J. U. T cell receptor (TCR) signaling in health and disease. Signal Transduct. Target. Ther. 6, 1\u201326 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2729_CR79","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1084\/jem.20022112","volume":"197","author":"D Filipp","year":"2003","unstructured":"Filipp, D. et al. Regulation of Fyn through translocation of activated Lck into lipid rafts. J. Exp. Med. 197, 1221 (2003).","journal-title":"J. Exp. Med."},{"key":"2729_CR80","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1007\/s00125-016-4202-2","volume":"60","author":"R Wu","year":"2017","unstructured":"Wu, R. et al. c-Abl inhibition mitigates diet-induced obesity through improving insulin sensitivity of subcutaneous fat in mice. Diabetologia 60, 900\u2013910 (2017).","journal-title":"Diabetologia"},{"key":"2729_CR81","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/jdi.12407","volume":"7","author":"H Sato","year":"2015","unstructured":"Sato, H. et al. Src regulates insulin secretion and glucose metabolism by influencing subcellular localization of glucokinase in pancreatic \u03b2-cells. J. Diab. Investig. 7, 171 (2015).","journal-title":"J. Diab. Investig."},{"key":"2729_CR82","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/S0960-9822(00)00024-5","volume":"11","author":"CC Yu","year":"2001","unstructured":"Yu, C. C., Yen, T. S., Lowell, C. A. & DeFranco, A. L. Lupus-like kidney disease in mice deficient in the Src family tyrosine kinases Lyn and Fyn. Curr. Biol. 11, 34\u201338 (2001).","journal-title":"Curr. Biol."},{"key":"2729_CR83","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-02162-3","volume":"8","author":"M Knoll","year":"2017","unstructured":"Knoll, M. et al. SYK kinase mediates brown fat differentiation and activation. Nat. Commun. 8, 1\u201311 (2017).","journal-title":"Nat. Commun."},{"key":"2729_CR84","first-page":"1","volume":"15","author":"W Zhao","year":"2024","unstructured":"Zhao, W. et al. The proto-oncogene tyrosine kinase c-SRC facilitates glioblastoma progression by remodeling fatty acid synthesis. Nat. Commun. 15, 1\u201318 (2024).","journal-title":"Nat. Commun."},{"key":"2729_CR85","first-page":"466","volume":"71","author":"KD Miller","year":"2021","unstructured":"Miller, K. D. et al. Cancer statistics for the US Hispanic\/Latino population, 2021. Ca. Cancer J. Clin. 71, 466\u2013487 (2021).","journal-title":"Ca. Cancer J. Clin."},{"key":"2729_CR86","first-page":"7","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. Ca. Cancer J. Clin. 70, 7\u201330 (2020).","journal-title":"Ca. Cancer J. Clin."},{"key":"2729_CR87","doi-asserted-by":"publisher","first-page":"105755","DOI":"10.1016\/j.ypmed.2019.105755","volume":"126","author":"BD Hallowell","year":"2019","unstructured":"Hallowell, B. D. et al. Cancer mortality rates among US and foreign-born individuals: United States 2005\u20132014. Prev. Med. 126, 105755 (2019).","journal-title":"Prev. Med."},{"key":"2729_CR88","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1002\/cncr.33632","volume":"127","author":"C Printz","year":"2021","unstructured":"Printz, C. US cancer death rate continues to decline. Cancer 127, 1733\u20131733 (2021).","journal-title":"Cancer"},{"key":"2729_CR89","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","volume":"40","author":"KM Sturgeon","year":"2019","unstructured":"Sturgeon, K. M. et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur. Heart J. 40, 3889\u20133897 (2019).","journal-title":"Eur. Heart J."},{"key":"2729_CR90","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1001\/jama.2020.7848","volume":"324","author":"L Orkaby","year":"2020","unstructured":"Orkaby, L. et al. Association of statin use with all-cause and cardiovascular mortality in US veterans 75 years and older. J. Am. Med. Assoc. 324, 68 (2020).","journal-title":"J. Am. Med. Assoc."},{"key":"2729_CR91","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1249\/MSS.0000000000001939","volume":"51","author":"WE Kraus","year":"2019","unstructured":"Kraus, W. E. et al. Physical activity, all-cause and cardiovascular mortality, and cardiovascular disease. Med. Sci. Sports Exerc. 51, 1270\u20131281 (2019).","journal-title":"Med. Sci. Sports Exerc."},{"key":"2729_CR92","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.suc.2022.01.008","volume":"102","author":"JL Peters","year":"2022","unstructured":"Peters, J. L. et al. Epidemiology of valvular heart disease. Surg. Clin. North Am. 102, 517\u2013528 (2022).","journal-title":"Surg. Clin. North Am."},{"key":"2729_CR93","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.2337\/dc24-0673","volume":"47","author":"W Dai","year":"2024","unstructured":"Dai, W. & Albrecht, S. S. Sitting time and its interaction with physical activity in relation to all-cause and heart disease mortality in U.S. adults with diabetes. Diabetes Care 47, 1764\u20131768 (2024).","journal-title":"Diabetes Care"},{"key":"2729_CR94","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40272-021-00457-z","volume":"23","author":"VC Trindade","year":"2021","unstructured":"Trindade, V. C., Carneiro-Sampaio, M., Bonfa, E. & Silva, C. A. An update on the management of childhood-onset systemic lupus erythematosus. Pediatr. Drugs 23, 331\u2013347 (2021).","journal-title":"Pediatr. Drugs"},{"key":"2729_CR95","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1001\/jama.2015.7008","volume":"314","author":"JE Di Angelantonio","year":"2015","unstructured":"Di Angelantonio, J. E. et al. Association of cardiometabolic multimorbidity with mortality. J. Am. Med. Assoc. 314, 52 (2015).","journal-title":"J. Am. Med. Assoc."},{"key":"2729_CR96","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s12944-024-02200-2","volume":"23","author":"L Ke","year":"2024","unstructured":"Ke, L., Zhao, L., Xing, W. & Tang, Q. Association between Parkinson\u2019s disease and cardiovascular disease mortality: a prospective population-based study from NHANES. Lipids Health Dis. 23, 212 (2024).","journal-title":"Lipids Health Dis."},{"key":"2729_CR97","doi-asserted-by":"publisher","first-page":"679","DOI":"10.3389\/fnins.2020.00679","volume":"14","author":"ML Cali\u00f3","year":"2020","unstructured":"Cali\u00f3, M. L. et al. Mitochondrial dysfunction, neurogenesis, and epigenetics: putative implications for amyotrophic lateral sclerosis neurodegeneration and treatment. Front. Neurosci. 14, 679 (2020).","journal-title":"Front. Neurosci."},{"key":"2729_CR98","first-page":"3275","volume":"16","author":"W Jiang","year":"2018","unstructured":"Jiang, W., Peng, Y. & Yang, K. Cellular signaling pathways regulating \u03b2-cell proliferation as a promising therapeutic target in the treatment of diabetes (Review). Exp. Ther. Med. 16, 3275\u20133285 (2018).","journal-title":"Exp. Ther. Med."},{"key":"2729_CR99","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.3390\/biomedicines9121789","volume":"9","author":"JP Shiau","year":"2021","unstructured":"Shiau, J. P. et al. FAK regulates VEGFR2 expression and promotes angiogenesis in triple-negative breast cancer. Biomedicines 9, 1789 (2021).","journal-title":"Biomedicines"},{"key":"2729_CR100","doi-asserted-by":"publisher","first-page":"503","DOI":"10.18632\/oncotarget.28434","volume":"14","author":"B Mezquita","year":"2023","unstructured":"Mezquita, B., Reyes-Farias, M. & Pons, M. Targeting the src N-terminal regulatory element in cancer. Oncotarget 14, 503\u2013513 (2023).","journal-title":"Oncotarget"},{"key":"2729_CR101","doi-asserted-by":"publisher","first-page":"102584","DOI":"10.1016\/j.jbc.2022.102584","volume":"298","author":"WM Alwanian","year":"2022","unstructured":"Alwanian, W. M., Vlajic, K., Bie, W., Kajdacsy-Balla, A. & Tyner, A. L. Protein tyrosine kinase 6 regulates activation of SRC kinase. J. Biol. Chem. 298, 102584 (2022).","journal-title":"J. Biol. Chem."},{"key":"2729_CR102","first-page":"1","volume":"6","author":"X Hu","year":"2021","unstructured":"Hu, X., Li, J., Fu, M., Zhao, X. & Wang, W. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct. Target. Ther. 6, 1\u201333 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2729_CR103","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1369\/0022155414561498","volume":"63","author":"H Yoon","year":"2015","unstructured":"Yoon, H., Dehart, J. P., Murphy, J. M. & Lim, S. T. S. Understanding the roles of FAK in cancer. J. Histochem. Cytochem. 63, 114\u2013128 (2015).","journal-title":"J. Histochem. Cytochem."},{"key":"2729_CR104","doi-asserted-by":"publisher","first-page":"114776","DOI":"10.1016\/j.expneurol.2024.114776","volume":"376","author":"Q Wu","year":"2024","unstructured":"Wu, Q. et al. LAMC1 attenuates neuronal apoptosis via FAK\/PI3K\/AKT signaling pathway after subarachnoid hemorrhage. Exp. Neurol. 376, 114776 (2024).","journal-title":"Exp. Neurol."},{"key":"2729_CR105","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1128\/MCB.24.10.4361-4371.2004","volume":"24","author":"E Kurenova","year":"2004","unstructured":"Kurenova, E. et al. Focal adhesion kinase suppresses apoptosis by binding to the death domain of receptor-interacting protein. Mol. Cell. Biol. 24, 4361\u20134371 (2004).","journal-title":"Mol. Cell. Biol."},{"key":"2729_CR106","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/biom14010029","volume":"14","author":"F Macr\u00ec","year":"2023","unstructured":"Macr\u00ec, F. et al. High phosphate-induced JAK-STAT signaling sustains vascular smooth muscle cell inflammation and limits calcification. Biomolecules 14, 29 (2023).","journal-title":"Biomolecules"},{"key":"2729_CR107","doi-asserted-by":"publisher","first-page":"823","DOI":"10.2174\/1874467214666210301121432","volume":"14","author":"N Kumar","year":"2021","unstructured":"Kumar, N., Sharma, N. & Mehan, S. Connection between JAK\/STAT and PPAR\u03b3 signaling during the progression of multiple sclerosis: insights into the modulation of t-cells and immune responses in the brain. Curr. Mol. Pharmacol. 14, 823\u2013837 (2021).","journal-title":"Curr. Mol. Pharmacol."},{"key":"2729_CR108","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s11899-019-00545-5","volume":"14","author":"G Shouse","year":"2019","unstructured":"Shouse, G. & Nikolaenko, L. Targeting the JAK\/STAT pathway in T cell lymphoproliferative disorders. Curr. Hematol. Malig. Rep. 14, 570\u2013576 (2019).","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"2729_CR109","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/s41588-021-00803-4","volume":"53","author":"AM Wang","year":"2021","unstructured":"Wang, A. M. et al. Gain-of-function variants in SYK cause immune dysregulation and systemic inflammation in humans and mice. Nat. Genet. 53, 500\u2013510 (2021).","journal-title":"Nat. Genet."},{"key":"2729_CR110","doi-asserted-by":"publisher","first-page":"593","DOI":"10.4111\/icu.20240250","volume":"65","author":"JN Ho","year":"2024","unstructured":"Ho, J. N., Byun, S. S., Kim, D., Ryu, H. & Lee, S. Dasatinib induces apoptosis and autophagy by suppressing the PI3K\/Akt\/mTOR pathway in bladder cancer cells. Investig. Clin. Urol. 65, 593 (2024).","journal-title":"Investig. Clin. Urol."},{"key":"2729_CR111","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.18632\/oncotarget.26621","volume":"10","author":"AR Dosch","year":"2019","unstructured":"Dosch, A. R. et al. Src kinase inhibition restores E-cadherin expression in dasatinib-sensitive pancreatic cancer cells. Oncotarget 10, 1056\u20131069 (2019).","journal-title":"Oncotarget"},{"key":"2729_CR112","doi-asserted-by":"publisher","first-page":"109651","DOI":"10.1016\/j.cellsig.2020.109651","volume":"72","author":"CA Hunter","year":"2020","unstructured":"Hunter, C. A., Koc, H. & Koc, E. C. c-Src kinase impairs the expression of mitochondrial OXPHOS complexes in liver cancer. Cell. Signal. 72, 109651 (2020).","journal-title":"Cell. Signal."},{"key":"2729_CR113","first-page":"1246","volume":"38","author":"ZC Song","year":"2017","unstructured":"Song, Z. C. et al. Effect of Src in cervical cancer cells proliferation and apoptosis via ERK signal transduction. pathway. Zhonghua Liu Xing Bing. Xue Za Zhi 38, 1246\u20131251 (2017).","journal-title":"Zhonghua Liu Xing Bing. Xue Za Zhi"},{"key":"2729_CR114","doi-asserted-by":"publisher","first-page":"595818","DOI":"10.3389\/fimmu.2020.595818","volume":"11","author":"E Aydin","year":"2021","unstructured":"Aydin, E. et al. Phosphoinositide 3-kinase signaling in the tumor microenvironment: what do we need to consider when treating chronic lymphocytic leukemia with PI3K inhibitors? Front. Immunol. 11, 595818 (2021).","journal-title":"Front. Immunol."},{"key":"2729_CR115","doi-asserted-by":"publisher","first-page":"ra40","DOI":"10.1126\/scisignal.2003936","volume":"6","author":"S Chen","year":"2013","unstructured":"Chen, S. et al. Tyrosine kinase BMX phosphorylates phosphotyrosine-primed motif mediating the activation of multiple receptor tyrosine kinases. Sci. Signal. 6, ra40 (2013).","journal-title":"Sci. Signal."},{"key":"2729_CR116","first-page":"63","volume":"21","author":"Z Chen","year":"2023","unstructured":"Chen, Z., Xiao, Y., Yang, P. & Wang, R. Pan-cancer analysis reveals SRC may link lipid metabolism and macrophages. Iran. J. Biotechnol. 21, 63\u201374 (2023).","journal-title":"Iran. J. Biotechnol."},{"key":"2729_CR117","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-021-01452-5","volume":"23","author":"YA Mohammed","year":"2021","unstructured":"Mohammed, Y. A. et al. Sublethal doxorubicin promotes migration and invasion of breast cancer cells: role of Src family non-receptor tyrosine kinases. Breast Cancer Res. 23, 76 (2021).","journal-title":"Breast Cancer Res."},{"key":"2729_CR118","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.3390\/ijms26073040","volume":"26","author":"CC Chen","year":"2025","unstructured":"Chen, C. C., Wang, S., Yang, J. M. & Huang, C. H. Targeting signaling excitability in cervical and pancreatic cancer cells through combined inhibition of FAK and PI3K. Int. J. Mol. Sci. 26, 3040 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"2729_CR119","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.3390\/ijms23031726","volume":"23","author":"HH Chuang","year":"2022","unstructured":"Chuang, H. H. et al. FAK in cancer: from mechanisms to therapeutic strategies. Int. J. Mol. Sci. 23, 1726 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"2729_CR120","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.ejso.2008.05.003","volume":"34","author":"P de Heer","year":"2008","unstructured":"de Heer, P. et al. Combined expression of the non-receptor protein tyrosine kinases FAK and Src in primary colorectal cancer is associated with tumor recurrence and metastasis formation. Eur. J. Surg. Oncol. 34, 1253\u20131261 (2008).","journal-title":"Eur. J. Surg. Oncol."},{"key":"2729_CR121","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jhep.2021.05.018","volume":"75","author":"X Song","year":"2021","unstructured":"Song, X. et al. Focal adhesion kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation. J. Hepatol. 75, 888\u2013899 (2021).","journal-title":"J. Hepatol."},{"key":"2729_CR122","doi-asserted-by":"publisher","first-page":"4273","DOI":"10.1038\/sj.onc.1203775","volume":"19","author":"PJ Mitchell","year":"2000","unstructured":"Mitchell, P. J., Sara, E. A. & Crompton, M. R. A novel adaptor-like protein which is a substrate for the non-receptor tyrosine kinase, BRK. Oncogene 19, 4273\u20134282 (2000).","journal-title":"Oncogene"},{"key":"2729_CR123","doi-asserted-by":"publisher","first-page":"110723","DOI":"10.1016\/j.cellsig.2023.110723","volume":"108","author":"A Mandapati","year":"2023","unstructured":"Mandapati, A., Ning, Z., Baharani, A. & Lukong, K. E. BRK confers tamoxifen-resistance in breast cancer via regulation of tyrosine phosphorylation of CDK1. Cell. Signal. 108, 110723 (2023).","journal-title":"Cell. Signal."},{"key":"2729_CR124","doi-asserted-by":"publisher","first-page":"10605","DOI":"10.1074\/jbc.M109.060459","volume":"285","author":"WT Prieto-Echag\u00fce","year":"2010","unstructured":"Prieto-Echag\u00fce, W. T. et al. Cancer-associated mutations activate the nonreceptor tyrosine kinase Ack1. J. Biol. Chem. 285, 10605\u201310615 (2010).","journal-title":"J. Biol. Chem."},{"key":"2729_CR125","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1016\/j.ajpath.2011.12.028","volume":"180","author":"K Mahajan","year":"2012","unstructured":"Mahajan, K. et al. Ack1 tyrosine kinase activation correlates with pancreatic cancer progression. Am. J. Pathol. 180, 1386\u20131393 (2012).","journal-title":"Am. J. Pathol."},{"key":"2729_CR126","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/intbio\/zyac004","volume":"14","author":"AD Simoni","year":"2022","unstructured":"Simoni, A. D., Huber, H. A., Georgia, S. K. & Finley, S. D. Phosphatases are predicted to govern prolactin-mediated JAK\u2013STAT signaling in pancreatic beta cells. Integr. Biol. 14, 37\u201348 (2022).","journal-title":"Integr. Biol."},{"key":"2729_CR127","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejca.2019.11.017","volume":"126","author":"T Bagratuni","year":"2020","unstructured":"Bagratuni, T. et al. JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK\/STAT signaling pathway in ovarian cancer. Eur. J. Cancer 126, 125\u2013135 (2020).","journal-title":"Eur. J. Cancer"},{"key":"2729_CR128","doi-asserted-by":"publisher","first-page":"HEP18","DOI":"10.2217\/hep-2020-0001","volume":"7","author":"JJH Tang","year":"2020","unstructured":"Tang, J. J. H., Thng, D. K. H., Lim, J. J. & Toh, T. B. JAK\/STAT signaling in hepatocellular carcinoma. Hepatic Oncol. 7, HEP18 (2020).","journal-title":"Hepatic Oncol."},{"key":"2729_CR129","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.3389\/fonc.2020.01132","volume":"10","author":"J Zhu","year":"2020","unstructured":"Zhu, J. et al. Comprehensive analysis of the immune implication of ACK1 gene in non-small cell lung cancer. Front. Oncol. 10, 1132 (2020).","journal-title":"Front. Oncol."},{"key":"2729_CR130","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.4049\/jimmunol.169.6.2813","volume":"169","author":"K Yasuda","year":"2002","unstructured":"Yasuda, K. et al. Cutting edge: Fyn is essential for tyrosine phosphorylation of Csk-binding protein\/phosphoprotein associated with glycolipid-enriched microdomains in lipid rafts in resting T cells. J. Immunol. 169, 2813\u20132817 (2002).","journal-title":"J. Immunol."},{"key":"2729_CR131","doi-asserted-by":"publisher","first-page":"653657","DOI":"10.3389\/fgene.2021.653657","volume":"12","author":"S Ling","year":"2021","unstructured":"Ling, S. et al. Significant gene biomarker tyrosine kinase non-receptor 2 mediated cell proliferation and invasion in colon cancer. Front. Genet. 12, 653657 (2021).","journal-title":"Front. Genet."},{"key":"2729_CR132","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1080\/15548627.2022.2103961","volume":"19","author":"S Chouhan","year":"2023","unstructured":"Chouhan, S. et al. TNK2\/ACK1-mediated phosphorylation of ATP5F1A (ATP synthase F1 subunit alpha) selectively augments survival of prostate cancer while engendering mitochondrial vulnerability. Autophagy 19, 1000\u20131025 (2023).","journal-title":"Autophagy"},{"key":"2729_CR133","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1001\/jama.2023.25881","volume":"331","author":"JL Caswell-Jin","year":"2024","unstructured":"Caswell-Jin, J. L. et al. Analysis of breast cancer mortality in the US\u20141975 to 2019. J. Am. Med. Assoc. 331, 233\u2013241 (2024).","journal-title":"J. Am. Med. Assoc."},{"key":"2729_CR134","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-022-01596-y","volume":"24","author":"J Luo","year":"2022","unstructured":"Luo, J. et al. SRC kinase-mediated signaling pathways and targeted therapies in breast cancer. Breast Cancer Res. 24, 99 (2022).","journal-title":"Breast Cancer Res."},{"key":"2729_CR135","doi-asserted-by":"publisher","first-page":"1866975","DOI":"10.1080\/23723556.2020.1866975","volume":"8","author":"SY Lin","year":"2021","unstructured":"Lin, S. Y. & Lin, S. C. SRC promotes lipogenesis: implications for obesity and breast cancer. Mol. Cell. Oncol. 8, 1866975 (2021).","journal-title":"Mol. Cell. Oncol."},{"key":"2729_CR136","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1200\/jco.2011.29.27_suppl.296","volume":"29","author":"RD Rao","year":"2011","unstructured":"Rao, R. D., Siziopikou, K. P. & Cobleigh, M. A. A phase II open-label trial to evaluate the efficacy and toxicity of erlotinib in women with metastatic, hormone receptor-negative, and HER2-negative breast cancer. J. Clin. Oncol. 29, 296 (2011).","journal-title":"J. Clin. Oncol."},{"key":"2729_CR137","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-30950-z","volume":"13","author":"C Mamot","year":"2023","unstructured":"Mamot, C. et al. A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer. Sci. Rep. 13, 3705 (2023).","journal-title":"Sci. Rep."},{"key":"2729_CR138","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1038\/s41388-023-02747-x","volume":"42","author":"M Sawant","year":"2023","unstructured":"Sawant, M. et al. Epigenetic reprogramming of cell cycle genes by ACK1 promotes breast cancer resistance to CDK4\/6 inhibitor. Oncogene 42, 2263\u20132277 (2023).","journal-title":"Oncogene"},{"key":"2729_CR139","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/j.0022-202X.2005.23685.x","volume":"124","author":"C Hoeller","year":"2005","unstructured":"Hoeller, C. et al. The Non-receptor-associated tyrosine kinase Syk is a regulator of metastatic behavior in human melanoma cells. J. Invest. Dermatol. 124, 1293\u20131299 (2005).","journal-title":"J. Invest. Dermatol."},{"key":"2729_CR140","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/jmcb\/mjad025","volume":"15","author":"X He","year":"2023","unstructured":"He, X. et al. CSF2 upregulates CXCL3 expression in adipocytes to promote metastasis of breast cancer via the FAK signaling pathway. J. Mol. Cell Biol. 15, 25 (2023).","journal-title":"J. Mol. Cell Biol."},{"key":"2729_CR141","doi-asserted-by":"publisher","first-page":"16605","DOI":"10.3390\/ijms242316605","volume":"24","author":"N Mubtasim","year":"2023","unstructured":"Mubtasim, N. & Gollahon, L. The Effect of adipocyte-secreted factors in activating focal adhesion kinase-mediated cell signaling pathway towards metastasis in breast cancer cells. Int. J. Mol. Sci. 24, 16605 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"2729_CR142","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/S0304-3835(02)00463-9","volume":"189","author":"T Toyama","year":"2003","unstructured":"Toyama, T. et al. Reduced expression of the Syk gene is correlated with poor prognosis in human breast cancer. Cancer Lett. 189, 97\u2013102 (2003).","journal-title":"Cancer Lett."},{"key":"2729_CR143","doi-asserted-by":"publisher","first-page":"101085","DOI":"10.1016\/j.drup.2024.101085","volume":"74","author":"Z Zhou","year":"2024","unstructured":"Zhou, Z. et al. Syk-dependent homologous recombination activation promotes cancer resistance to DNA targeted therapy. Drug Resist. Updat. 74, 101085 (2024).","journal-title":"Drug Resist. Updat."},{"key":"2729_CR144","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03156-8","volume":"11","author":"P Polak","year":"2020","unstructured":"Polak, P. et al. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism. Cell Death Dis. 11, 956 (2020).","journal-title":"Cell Death Dis."},{"key":"2729_CR145","doi-asserted-by":"publisher","first-page":"e56071","DOI":"10.1371\/journal.pone.0056071","volume":"8","author":"D Hu","year":"2013","unstructured":"Hu, D. et al. Adiponectin regulates vascular endothelial growth factor-c expression in macrophages via Syk-ERK pathway. PLoS ONE 8, e56071 (2013).","journal-title":"PLoS ONE"},{"key":"2729_CR146","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10585-011-9437-1","volume":"29","author":"QXA Sang","year":"2012","unstructured":"Sang, Q. X. A. et al. Non-receptor tyrosine kinase 2 reaches its lowest expression levels in human breast cancer during regional nodal metastasis. Clin. Exp. Metastasis 29, 143\u2013153 (2012).","journal-title":"Clin. Exp. Metastasis"},{"key":"2729_CR147","doi-asserted-by":"publisher","first-page":"560","DOI":"10.3389\/fonc.2018.00560","volume":"8","author":"O Raivola","year":"2018","unstructured":"Raivola, O. et al. Hyperactivation of oncogenic JAK3 mutants depend on ATP binding to the pseudokinase domain. Front. Oncol. 8, 560 (2018).","journal-title":"Front. Oncol."},{"key":"2729_CR148","doi-asserted-by":"publisher","first-page":"29022","DOI":"10.1074\/jbc.M115.670224","volume":"290","author":"E Losdyck","year":"2015","unstructured":"Losdyck, E. et al. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus kinase 3 (JAK3) mutants exhibit different cytokine-receptor requirements and JAK inhibitor specificities. J. Biol. Chem. 290, 29022\u201329034 (2015).","journal-title":"J. Biol. Chem."},{"key":"2729_CR149","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1182\/blood-2009-09-245498","volume":"115","author":"T Hornakova","year":"2010","unstructured":"Hornakova, T. et al. ALL-associated JAK1 mutations confer hypersensitivity to the antiproliferative effect of type I interferon. Blood 115, 3287\u20133295 (2010).","journal-title":"Blood"},{"key":"2729_CR150","doi-asserted-by":"publisher","first-page":"6773","DOI":"10.1074\/jbc.M807531200","volume":"284","author":"T Hornakova","year":"2009","unstructured":"Hornakova, T. et al. Acute Lymphoblastic Leukemia-associated JAK1 mutants activate the Janus kinase\/STAT pathway via interleukin-9 receptor \u03b1 homodimers. J. Biol. Chem. 284, 6773\u20136781 (2009).","journal-title":"J. Biol. Chem."},{"key":"2729_CR151","doi-asserted-by":"publisher","first-page":"34687","DOI":"10.18632\/oncotarget.16670","volume":"8","author":"Q Li","year":"2017","unstructured":"Li, Q. et al. Identification of a novel functional JAK1 S646P mutation in acute lymphoblastic leukemia. Oncotarget 8, 34687\u201334697 (2017).","journal-title":"Oncotarget"},{"key":"2729_CR152","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1182\/blood-2017-07-797597","volume":"131","author":"S Degryse","year":"2018","unstructured":"Degryse, S. et al. Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL. Blood 131, 421\u2013425 (2018).","journal-title":"Blood"},{"key":"2729_CR153","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/kinasesphosphatases3020010","volume":"3","author":"Z Qusairy","year":"2025","unstructured":"Qusairy, Z. & Rada, M. Bruton\u2019s Tyrosine Kinase: A Double-Edged sword in cancer and aging. Kinases Phosphatases 3, 10 (2025).","journal-title":"Kinases Phosphatases"},{"key":"2729_CR154","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.70005","volume":"358","author":"A Irgit","year":"2025","unstructured":"Irgit, A. et al. Structure and dynamics of the ABL1 tyrosine kinase and its important role in chronic myeloid leukemia. Arch. Pharm. 358, e70005 (2025).","journal-title":"Arch. Pharm."},{"key":"2729_CR155","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-021-00739-6","volume":"19","author":"JH Luttman","year":"2021","unstructured":"Luttman, J. H., Colemon, A., Mayro, B. & Pendergast, A. M. Role of the ABL tyrosine kinases in the epithelial\u2013mesenchymal transition and the metastatic cascade. Cell Commun. Signal. 19, 59 (2021).","journal-title":"Cell Commun. Signal."},{"key":"2729_CR156","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1111\/bph.16304","volume":"183","author":"Z Qu","year":"2024","unstructured":"Qu, Z., Dong, J. & Zhang, Z. Y. Protein tyrosine phosphatases as emerging targets for cancer immunotherapy. Br. J. Pharmacol. 183, 1233\u20131249 (2024).","journal-title":"Br. J. Pharmacol."},{"key":"2729_CR157","doi-asserted-by":"publisher","first-page":"12865","DOI":"10.3390\/ijms222312865","volume":"22","author":"V Sivaganesh","year":"2021","unstructured":"Sivaganesh, V. et al. Protein tyrosine phosphatases: mechanisms in cancer. Int. J. Mol. Sci. 22, 12865 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"2729_CR158","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-85445-w","volume":"15","author":"X Li","year":"2025","unstructured":"Li, X., Zhang, H., Dong, J. & Wang, J. Tyrosine phosphatase SHP2 accelerated ovarian cancer via modulating integrin\/E-Cadherin\/ZEB1 induced EMT. Sci. Rep. 15, 1535 (2025).","journal-title":"Sci. Rep."},{"key":"2729_CR159","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abk3338","volume":"8","author":"PK Goh","year":"2022","unstructured":"Goh, P. K. et al. PTPN2 elicits cell autonomous and non\u2013cell autonomous effects on antitumor immunity in triple-negative breast cancer. Sci. Adv. 8, eabk3338 (2022).","journal-title":"Sci. Adv."},{"key":"2729_CR160","doi-asserted-by":"publisher","first-page":"1362224","DOI":"10.3389\/fimmu.2024.1362224","volume":"15","author":"S Ilangumaran","year":"2024","unstructured":"Ilangumaran, S., Gui, Y., Shukla, A. & Ramanathan, S. SOCS1 expression in cancer cells: potential roles in promoting antitumor immunity. Front. Immunol. 15, 1362224 (2024).","journal-title":"Front. Immunol."},{"key":"2729_CR161","doi-asserted-by":"publisher","first-page":"1449397","DOI":"10.3389\/fimmu.2024.1449397","volume":"15","author":"DM Lynch","year":"2024","unstructured":"Lynch, D. M., Forrester, B., Webb, T. & Ciulli, A. Unravelling the druggability and immunological roles of the SOCS-family proteins. Front. Immunol. 15, 1449397 (2024).","journal-title":"Front. Immunol."},{"key":"2729_CR162","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s10565-023-09798-6","volume":"39","author":"X Liu","year":"2023","unstructured":"Liu, X., Liu, F., Cai, M. & Fang, H. Therapeutic values of engineered immune cells: a precision-guided weapon. Cell Biol. Toxicol. 39, 367\u2013369 (2023).","journal-title":"Cell Biol. Toxicol."},{"key":"2729_CR163","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3892\/ol.2021.13123","volume":"23","author":"L Dai","year":"2021","unstructured":"Dai, L. et al. SOCS proteins and their roles in the development of glioblastoma (Review). Oncol. Lett. 23, 5 (2021).","journal-title":"Oncol. Lett."},{"key":"2729_CR164","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1242\/jcs.182097","volume":"129","author":"A Yurdagul","year":"2016","unstructured":"Yurdagul, A. et al. Oxidized LDL induces FAK-dependent RSK signaling to drive NF-\u03baB activation and VCAM-1 expression. J. Cell Sci. 129, 1580\u20131591 (2016).","journal-title":"J. Cell Sci."},{"key":"2729_CR165","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jacc.2017.05.035","volume":"70","author":"JC M\u00fcnzel","year":"2017","unstructured":"M\u00fcnzel, J. C. et al. Impact of oxidative stress on the heart and vasculature. J. Am. Coll. Cardiol. 70, 212\u2013229 (2017).","journal-title":"J. Am. Coll. Cardiol."},{"key":"2729_CR166","doi-asserted-by":"publisher","first-page":"256","DOI":"10.21037\/atm.2018.06.21","volume":"6","author":"G Siasos","year":"2018","unstructured":"Siasos, G. et al. Mitochondria and cardiovascular diseases-from pathophysiology to treatment. Ann. Transl. Med. 6, 256 (2018).","journal-title":"Ann. Transl. Med."},{"key":"2729_CR167","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1006\/jmcc.2001.1427","volume":"33","author":"Y Takeishi","year":"2001","unstructured":"Takeishi, Y. et al. Src and Multiple MAP kinase activation in cardiac hypertrophy and congestive heart failure under chronic pressure-overload: comparison with acute mechanical stretch. J. Mol. Cell. Cardiol. 33, 1637\u20131648 (2001).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"2729_CR168","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.3390\/ijms25021206","volume":"25","author":"J Sun","year":"2024","unstructured":"Sun, J. et al. Sophoridine counteracts obesity via src-mediated inhibition of VEGFR expression and PI3K\/AKT phosphorylation. Int. J. Mol. Sci. 25, 1206 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2729_CR169","doi-asserted-by":"publisher","first-page":"5365","DOI":"10.4049\/jimmunol.1103553","volume":"188","author":"P Jayaraman","year":"2012","unstructured":"Jayaraman, P. et al. Tumor-Expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release. J. Immunol. 188, 5365\u20135376 (2012).","journal-title":"J. Immunol."},{"key":"2729_CR170","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1021\/acschembio.4c00048","volume":"19","author":"H Zhang","year":"2024","unstructured":"Zhang, H. et al. Discovery of a covalent inhibitor selectively targeting the autophosphorylation site of c-Src kinase. ACS Chem. Biol. 19, 999\u20131010 (2024).","journal-title":"ACS Chem. Biol."},{"key":"2729_CR171","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.neuroscience.2013.12.060","volume":"262","author":"L Zan","year":"2014","unstructured":"Zan, L. et al. Src regulates angiogenic factors and vascular permeability after focal cerebral ischemia\u2013reperfusion. Neuroscience 262, 118\u2013128 (2014).","journal-title":"Neuroscience"},{"key":"2729_CR172","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1007\/s00134-012-2498-z","volume":"38","author":"M Oyaizu","year":"2012","unstructured":"Oyaizu, M. et al. Src tyrosine kinase inhibition prevents pulmonary ischemia\u2013reperfusion-induced acute lung injury. Intensive Care Med. 38, 894\u2013905 (2012).","journal-title":"Intensive Care Med."},{"key":"2729_CR173","doi-asserted-by":"publisher","first-page":"114863","DOI":"10.1016\/j.expneurol.2024.114863","volume":"379","author":"H Wang","year":"2024","unstructured":"Wang, H. et al. IL-17A exacerbates caspase-12-dependent neuronal apoptosis following ischemia through the Src-PLC\u03b3-calpain pathway. Exp. Neurol. 379, 114863 (2024).","journal-title":"Exp. Neurol."},{"key":"2729_CR174","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13075-018-1582-3","volume":"20","author":"S Jo","year":"2018","unstructured":"Jo, S. et al. IL-17A induces osteoblast differentiation by activating JAK2\/STAT3 in ankylosing spondylitis. Arthritis Res. Ther. 20, 115 (2018).","journal-title":"Arthritis Res. Ther."},{"key":"2729_CR175","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/ng.3815","volume":"49","author":"X Wang","year":"2017","unstructured":"Wang, X. et al. Germline mutations in ABL1 cause an autosomal dominant syndrome characterized by congenital heart defects and skeletal malformations. Nat. Genet. 49, 613\u2013617 (2017).","journal-title":"Nat. Genet."},{"key":"2729_CR176","doi-asserted-by":"publisher","first-page":"4980","DOI":"10.3390\/ijms22094980","volume":"22","author":"I Roger","year":"2021","unstructured":"Roger, I., Milara, J., Montero, P. & Cortijo, J. The role of JAK\/STAT molecular pathway in vascular remodeling associated with pulmonary hypertension. Int. J. Mol. Sci. 22, 4980 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"2729_CR177","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.jhep.2020.05.028","volume":"73","author":"S Pang","year":"2020","unstructured":"Pang, S. et al. Peptide SMIM30 promotes HCC development by inducing SRC\/YES1 membrane anchoring and MAPK pathway activation. J. Hepatol. 73, 1155\u20131169 (2020).","journal-title":"J. Hepatol."},{"key":"2729_CR178","doi-asserted-by":"publisher","first-page":"1003852","DOI":"10.3389\/fcvm.2022.1003852","volume":"9","author":"J Ma","year":"2022","unstructured":"Ma, J. & Chen, X. Advances in pathogenesis and treatment of essential hypertension. Front. Cardiovasc. Med. 9, 1003852 (2022).","journal-title":"Front. Cardiovasc. Med."},{"key":"2729_CR179","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/IBPC.S223334","volume":"13","author":"MK Pathan","year":"2020","unstructured":"Pathan, M. K. & Cohen, D. L. Resistant hypertension: where are we now and where do we go from here? Integr. Blood Press. Control 13, 83\u201393 (2020).","journal-title":"Integr. Blood Press. Control"},{"key":"2729_CR180","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e14916","volume":"9","author":"X Yang","year":"2023","unstructured":"Yang, X., Yang, Y., Liu, K. & Zhang, C. Traditional Chinese medicine monomers: Targeting pulmonary artery smooth muscle cells proliferation to treat pulmonary hypertension. Heliyon 9, e14916 (2023).","journal-title":"Heliyon"},{"key":"2729_CR181","doi-asserted-by":"publisher","first-page":"7057","DOI":"10.1073\/pnas.1800440115","volume":"115","author":"JJ Lee","year":"2018","unstructured":"Lee, J. J. et al. Inhibition of epithelial cell migration and Src\/FAK signaling by SIRT3. Proc. Natl. Acad. Sci. USA 115, 7057\u20137062 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2729_CR182","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.3390\/cells10123538","volume":"10","author":"JB G\u00e9m","year":"2021","unstructured":"G\u00e9m, J. B. et al. Characterization of type 1 angiotensin II receptor activation induced dual-specificity MAPK phosphatase gene expression changes in rat vascular smooth muscle cells. Cells 10, 3538 (2021).","journal-title":"Cells"},{"key":"2729_CR183","doi-asserted-by":"publisher","first-page":"10141","DOI":"10.7150\/thno.46985","volume":"10","author":"J Jin","year":"2020","unstructured":"Jin, J. et al. The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination. Theranostics 10, 10141\u201310153 (2020).","journal-title":"Theranostics"},{"key":"2729_CR184","doi-asserted-by":"publisher","first-page":"4389","DOI":"10.1093\/eurheartj\/ehab447","volume":"42","author":"C Baldini","year":"2021","unstructured":"Baldini, C., Moriconi, F. R., Galimberti, S., Libby, P. & De Caterina, R. The JAK\u2013STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms. Eur. Heart J. 42, 4389\u20134400 (2021).","journal-title":"Eur. Heart J."},{"key":"2729_CR185","doi-asserted-by":"publisher","first-page":"3151","DOI":"10.2147\/DMSO.S465755","volume":"17","author":"X Guan","year":"2024","unstructured":"Guan, X. et al. FAK family kinases: a potential therapeutic target for atherosclerosis. Diab. Metab. Syndr. Obes. 17, 3151\u20133161 (2024).","journal-title":"Diab. Metab. Syndr. Obes."},{"key":"2729_CR186","doi-asserted-by":"publisher","first-page":"3630","DOI":"10.3390\/ijms21103630","volume":"21","author":"JM Murphy","year":"2020","unstructured":"Murphy, J. M., Jeong, K. & Lim, S. T. S. FAK family kinases in vascular diseases. Int. J. Mol. Sci. 21, 3630 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"2729_CR187","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.cardiores.2005.04.017","volume":"67","author":"H Sato","year":"2005","unstructured":"Sato, H. et al. Mitochondrial reactive oxygen species and c-Src play a critical role in hypoxic response in vascular smooth muscle cells. Cardiovasc. Res. 67, 714\u2013722 (2005).","journal-title":"Cardiovasc. Res."},{"key":"2729_CR188","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-019-4220-5","volume":"12","author":"T Yamaura","year":"2019","unstructured":"Yamaura, T., Kasaoka, T., Iijima, N., Kimura, M. & Hatakeyama, S. Evaluation of therapeutic effects of FAK inhibition in murine models of atherosclerosis. BMC Res. Notes 12, 200 (2019).","journal-title":"BMC Res. Notes"},{"key":"2729_CR189","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1006\/jmcc.2002.2076","volume":"34","author":"GW Booz","year":"2002","unstructured":"Booz, G. W., Day, J. N. E. & Baker, K. M. Interplay between the cardiac renin angiotensin system and jak-stat signaling: role in cardiac hypertrophy, ischemia\/reperfusion dysfunction, and heart failure. J. Mol. Cell. Cardiol. 34, 1443\u20131453 (2002).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"2729_CR190","unstructured":"Shams, P., Malik, A. & Chhabra, L. Heart Failure (Congestive Heart Failure) (StatPearls Publishing, 2025)."},{"key":"2729_CR191","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.yjmcc.2008.10.017","volume":"46","author":"ZS Hakim","year":"2009","unstructured":"Hakim, Z. S. et al. FAK regulates cardiomyocyte survival following ischemia\/reperfusion. J. Mol. Cell. Cardiol. 46, 241\u2013248 (2009).","journal-title":"J. Mol. Cell. Cardiol."},{"key":"2729_CR192","doi-asserted-by":"publisher","first-page":"13207","DOI":"10.3390\/ijms252313207","volume":"25","author":"Y Liu","year":"2024","unstructured":"Liu, Y., Yang, Z., Zhou, X., Li, Z. & Hideki, N. Diacylglycerol kinases and its role in lipid metabolism and related diseases. Int. J. Mol. Sci. 25, 13207 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2729_CR193","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/iub.2559","volume":"74","author":"C Chang","year":"2021","unstructured":"Chang, C., Lin, C., Chen, B., Lin, P. & Chen, C. SHP2: The protein tyrosine phosphatase involved in chronic pulmonary inflammation and fibrosis. IUBMB Life 74, 131\u2013142 (2021).","journal-title":"IUBMB Life"},{"key":"2729_CR194","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.semcdb.2014.09.013","volume":"37","author":"J Lauriol","year":"2015","unstructured":"Lauriol, J., Jaffr\u00e9, F. & Kontaridis, M. I. The role of the protein tyrosine phosphatase SHP2 in cardiac development and disease. Semin. Cell Dev. Biol. 37, 73\u201381 (2015).","journal-title":"Semin. Cell Dev. Biol."},{"key":"2729_CR195","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1161\/CIRCULATIONAHA.107.728865","volume":"117","author":"MI Kontaridis","year":"2008","unstructured":"Kontaridis, M. I. et al. Deletion of Ptpn11 (Shp2) in cardiomyocytes causes dilated cardiomyopathy via effects on the extracellular signal\u2013regulated kinase\/mitogen-activated protein kinase and rhoa signaling pathways. Circulation 117, 1423\u20131435 (2008).","journal-title":"Circulation"},{"key":"2729_CR196","doi-asserted-by":"publisher","first-page":"e008865","DOI":"10.1161\/JAHA.118.008865","volume":"7","author":"T Dung Nguyen","year":"2018","unstructured":"Dung Nguyen, T. et al. Increased protein tyrosine phosphatase 1B (PTP1B) activity and cardiac insulin resistance precede mitochondrial and contractile dysfunction in pressure-overloaded hearts. J. Am. Heart Assoc. 7, e008865 (2018).","journal-title":"J. Am. Heart Assoc."},{"key":"2729_CR197","doi-asserted-by":"publisher","first-page":"1445739","DOI":"10.3389\/fcvm.2024.1445739","volume":"11","author":"Y Sun","year":"2024","unstructured":"Sun, Y., Dinenno, F. A., Tang, P. & Kontaridis, M. I. Protein tyrosine phosphatase 1B in metabolic and cardiovascular diseases: from mechanisms to therapeutics. Front. Cardiovasc. Med. 11, 1445739 (2024).","journal-title":"Front. Cardiovasc. Med."},{"key":"2729_CR198","doi-asserted-by":"publisher","first-page":"107258","DOI":"10.1016\/j.carpath.2020.107258","volume":"49","author":"Y Huang","year":"2020","unstructured":"Huang, Y. et al. Correlation between SHP-1 and carotid plaque vulnerability in humans. Cardiovasc. Pathol. 49, 107258 (2020).","journal-title":"Cardiovasc. Pathol."},{"key":"2729_CR199","doi-asserted-by":"publisher","first-page":"e0127942","DOI":"10.1371\/journal.pone.0127942","volume":"10","author":"T Nagata","year":"2015","unstructured":"Nagata, T. et al. Cardiac-Specific SOCS3 deletion prevents in vivo myocardial ischemia reperfusion injury through sustained activation of cardioprotective signaling molecules. PLoS ONE 10, e0127942\u2013e0127942 (2015).","journal-title":"PLoS ONE"},{"key":"2729_CR200","doi-asserted-by":"publisher","first-page":"13080","DOI":"10.3389\/jpps.2024.13080","volume":"27","author":"EB Ketema","year":"2024","unstructured":"Ketema, E. B. & Lopaschuk, G. D. The role of acetylation in obesity-induced cardiac metabolic alterations. J. Pharm. Pharm. Sci. 27, 13080 (2024).","journal-title":"J. Pharm. Pharm. Sci."},{"key":"2729_CR201","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.3390\/biomedicines11082309","volume":"11","author":"T Marshall","year":"2023","unstructured":"Marshall, T., Chen, J. & Viloria-Petit, A. M. Adipocyte-derived adipokines and other obesity-associated molecules in feline mammary cancer. Biomedicines 11, 2309 (2023).","journal-title":"Biomedicines"},{"key":"2729_CR202","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-017-02074-2","volume":"8","author":"X Brenachot","year":"2017","unstructured":"Brenachot, X. et al. Hepatic protein tyrosine phosphatase receptor gamma links obesity-induced inflammation to insulin resistance. Nat. Commun. 8, 1\u20139 (2017).","journal-title":"Nat. Commun."},{"key":"2729_CR203","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.7150\/ijbs.27173","volume":"14","author":"X Huang","year":"2018","unstructured":"Huang, X., Liu, G., Guo, J. & Su, Z. The PI3K\/AKT pathway in obesity and type 2 diabetes. Int. J. Biol. Sci. 14, 1483\u20131496 (2018).","journal-title":"Int. J. Biol. Sci."},{"key":"2729_CR204","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1093\/abbs\/gmv079","volume":"47","author":"KL Ma","year":"2015","unstructured":"Ma, K. L. et al. Inflammatory stress induces lipid accumulation in multi-organs of db\/db mice. Acta Biochim. Biophys. Sin. 47, 767\u2013774 (2015).","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"2729_CR205","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.1038\/emm.2016.81","volume":"48","author":"SM Jeon","year":"2016","unstructured":"Jeon, S. M. Regulation and function of AMPK in physiology and diseases. Exp. Mol. Med. 48, e245\u2013e245 (2016).","journal-title":"Exp. Mol. Med."},{"key":"2729_CR206","doi-asserted-by":"publisher","DOI":"10.1038\/srep38751","volume":"6","author":"T Honda","year":"2016","unstructured":"Honda, T. et al. Protective role for lipid modifications of Src-family kinases against chromosome missegregation. Sci. Rep. 6, 38751 (2016).","journal-title":"Sci. Rep."},{"key":"2729_CR207","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.3390\/ijms19061811","volume":"19","author":"T Morinaga","year":"2018","unstructured":"Morinaga, T., Yamaguchi, N., Nakayama, Y., Tagawa, M. & Yamaguchi, N. Role of membrane cholesterol levels in activation of Lyn upon cell detachment. Int. J. Mol. Sci. 19, 1811 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"2729_CR208","doi-asserted-by":"publisher","first-page":"707529","DOI":"10.3389\/fcvm.2021.707529","volume":"8","author":"K Malekmohammad","year":"2021","unstructured":"Malekmohammad, K., Bezsonov, E. E. & Rafieian-Kopaei, M. Role of lipid accumulation and inflammation in atherosclerosis: focus on molecular and cellular mechanisms. Front. Cardiovasc. Med. 8, 707529 (2021).","journal-title":"Front. Cardiovasc. Med."},{"key":"2729_CR209","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1161\/CIRCRESAHA.108.187302","volume":"104","author":"MJ Frontini","year":"2009","unstructured":"Frontini, M. J. et al. Lipid incorporation inhibits src-dependent assembly of fibronectin and type I collagen by vascular smooth muscle cells. Circ. Res. 104, 832\u2013841 (2009).","journal-title":"Circ. Res."},{"key":"2729_CR210","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1161\/CIRCRESAHA.117.311069","volume":"121","author":"S Biswas","year":"2017","unstructured":"Biswas, S., Zimman, A., Gao, D., Byzova, T. V. & Podrez, E. A. TLR2 plays a key role in platelet hyperreactivity and accelerated thrombosis associated with hyperlipidemia. Circ. Res. 121, 951\u2013962 (2017).","journal-title":"Circ. Res."},{"key":"2729_CR211","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.cmet.2007.04.005","volume":"5","author":"CC Bastie","year":"2007","unstructured":"Bastie, C. C. et al. Integrative metabolic regulation of peripheral tissue fatty acid oxidation by the SRC kinase family member Fyn. Cell Metab. 5, 371\u2013381 (2007).","journal-title":"Cell Metab."},{"key":"2729_CR212","doi-asserted-by":"publisher","first-page":"1","DOI":"10.26508\/lsa.202403019","volume":"8","author":"IL Mohammad","year":"2025","unstructured":"Mohammad, I. L. et al. Lipid-driven Src self-association modulates its transformation capacity. Life Sci. Alliance 8, 1\u201312 (2025).","journal-title":"Life Sci. Alliance"},{"key":"2729_CR213","doi-asserted-by":"publisher","first-page":"33944","DOI":"10.18632\/oncotarget.5580","volume":"6","author":"A Iurlo","year":"2015","unstructured":"Iurlo, A. et al. Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem? Oncotarget 6, 33944\u201333951 (2015).","journal-title":"Oncotarget"},{"key":"2729_CR214","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1072806","volume":"12","author":"C Li","year":"2022","unstructured":"Li, C. et al. Alterations in cellular metabolisms after TKI therapy for Philadelphia chromosome-positive leukemia in children: a review. Front Oncol. 12, 1072806 (2022).","journal-title":"Front Oncol."},{"key":"2729_CR215","doi-asserted-by":"publisher","first-page":"234","DOI":"10.4078\/jrd.2023.0030","volume":"30","author":"JH Koh","year":"2023","unstructured":"Koh, J. H., Lee, B. W. & Kim, W. U. Changes in the cholesterol profile of patients with rheumatoid arthritis treated with biologics or Janus kinase inhibitors. J. Rheum. Dis. 30, 234\u2013242 (2023).","journal-title":"J. Rheum. Dis."},{"key":"2729_CR216","doi-asserted-by":"publisher","first-page":"1245535","DOI":"10.3389\/fphar.2023.1245535","volume":"14","author":"D Collotta","year":"2023","unstructured":"Collotta, D., Franchina, M. P., Carlucci, V. & Collino, M. Recent advances in JAK inhibitors for the treatment of metabolic syndrome. Front. Pharmacol. 14, 1245535 (2023).","journal-title":"Front. Pharmacol."},{"key":"2729_CR217","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms14360","volume":"8","author":"CT Luk","year":"2017","unstructured":"Luk, C. T. et al. FAK signalling controls insulin sensitivity through regulation of adipocyte survival. Nat. Commun. 8, 1\u201313 (2017).","journal-title":"Nat. Commun."},{"key":"2729_CR218","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/jcmm.13001","volume":"21","author":"M Hu","year":"2017","unstructured":"Hu, M. et al. FAK contributes to proteinuria in hypercholesterolaemic rats and modulates podocyte F-actin re-organization via activating p38 in response to ox-LDL. J. Cell. Mol. Med. 21, 552\u2013567 (2017).","journal-title":"J. Cell. Mol. Med."},{"key":"2729_CR219","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-82426-7","volume":"11","author":"M Caterino","year":"2021","unstructured":"Caterino, M. et al. Dysregulation of lipid metabolism and pathological inflammation in patients with COVID-19. Sci. Rep. 11, 1\u201310 (2021).","journal-title":"Sci. Rep."},{"key":"2729_CR220","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-17027-5","volume":"11","author":"T van der Wel","year":"2020","unstructured":"van der Wel, T. et al. Chemical genetics strategy to profile kinase target engagement reveals role of FES in neutrophil phagocytosis. Nat. Commun. 11, 1\u201320 (2020).","journal-title":"Nat. Commun."},{"key":"2729_CR221","doi-asserted-by":"publisher","first-page":"1145826","DOI":"10.3389\/fimmu.2023.1145826","volume":"14","author":"BJ Laight","year":"2023","unstructured":"Laight, B. J. et al. Establishing the role of the FES tyrosine kinase in the pathogenesis, pathophysiology, and severity of sepsis and its outcomes. Front. Immunol. 14, 1145826 (2023).","journal-title":"Front. Immunol."},{"key":"2729_CR222","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1161\/CIRCRESAHA.122.321146","volume":"131","author":"E Karamanavi","year":"2022","unstructured":"Karamanavi, E. et al. The FES gene at the 15q26 coronary-artery-disease locus inhibits atherosclerosis. Circ. Res. 131, 1004 (2022).","journal-title":"Circ. Res."},{"key":"2729_CR223","doi-asserted-by":"publisher","first-page":"1206539","DOI":"10.3389\/fcell.2023.1206539","volume":"11","author":"S Zhu","year":"2023","unstructured":"Zhu, S., Wang, H., Ranjan, K. & Zhang, D. Regulation, targets and functions of CSK. Front. Cell Dev. Biol. 11, 1206539 (2023).","journal-title":"Front. Cell Dev. Biol."},{"key":"2729_CR224","doi-asserted-by":"publisher","first-page":"e32378","DOI":"10.1371\/journal.pone.0032378","volume":"7","author":"SH Choi","year":"2012","unstructured":"Choi, S. H., Wiesner, P., Almazan, F., Kim, J. & Miller, Y. I. Spleen tyrosine kinase regulates AP-1 dependent transcriptional response to minimally oxidized LDL. PLoS ONE 7, e32378 (2012).","journal-title":"PLoS ONE"},{"key":"2729_CR225","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1016\/j.cellsig.2004.03.015","volume":"16","author":"T Rosenzweig","year":"2004","unstructured":"Rosenzweig, T., Aga-Mizrachi, S., Bak, A. & Sampson, S. R. Src tyrosine kinase regulates insulin-induced activation of protein kinase C (PKC) \u03b4 in skeletal muscle. Cell. Signal. 16, 1299\u20131308 (2004).","journal-title":"Cell. Signal."},{"key":"2729_CR226","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.cmet.2017.03.018","volume":"25","author":"S Morita","year":"2017","unstructured":"Morita, S. et al. Targeting ABL-IRE1\u03b1 signaling spares ER-stressed pancreatic \u03b2-cells to reverse autoimmune diabetes. Cell Metab. 25, 883 (2017).","journal-title":"Cell Metab."},{"key":"2729_CR227","doi-asserted-by":"publisher","first-page":"e97694","DOI":"10.1371\/journal.pone.0097694","volume":"9","author":"CQ Xia","year":"2014","unstructured":"Xia, C. Q. et al. C-Abl inhibitor imatinib enhances insulin production by \u03b2 cells: C-Abl negatively regulates insulin production via interfering with the expression of NKx2.2 and GLUT-2. PLoS ONE 9, e97694 (2014).","journal-title":"PLoS ONE"},{"key":"2729_CR228","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2337\/db08-1328","volume":"58","author":"CC Berthier","year":"2009","unstructured":"Berthier, C. C. et al. Enhanced expression of Janus kinase\u2013signal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes 58, 469\u2013477 (2009).","journal-title":"Diabetes"},{"key":"2729_CR229","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.2337\/db11-1344","volume":"61","author":"EP Cai","year":"2012","unstructured":"Cai, E. P. et al. In vivo role of focal adhesion kinase in regulating pancreatic \u03b2-cell mass and function through insulin signaling, actin dynamics, and granule trafficking. Diabetes 61, 1708\u20131718 (2012).","journal-title":"Diabetes"},{"key":"2729_CR230","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3892\/ijmm.2021.5010","volume":"48","author":"J Zhao","year":"2021","unstructured":"Zhao, J., Chen, J., Li, Y. Y., Xia, L. L. & Wu, Y. G. Bruton\u2019s tyrosine kinase regulates macrophage\u2011induced inflammation in the diabetic kidney via NLRP3 inflammasome activation. Int. J. Mol. Med. 48, 177 (2021).","journal-title":"Int. J. Mol. Med."},{"key":"2729_CR231","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1161\/CIRCRESAHA.119.315896","volume":"126","author":"H Wu","year":"2020","unstructured":"Wu, H. & Ballantyne, C. M. Metabolic inflammation and insulin resistance in obesity. Circ. Res. 126, 1549\u20131564 (2020).","journal-title":"Circ. Res."},{"key":"2729_CR232","doi-asserted-by":"publisher","first-page":"5422","DOI":"10.1074\/jbc.274.9.5422","volume":"274","author":"C Arbet-Engels","year":"1999","unstructured":"Arbet-Engels, C., Tartare-Deckert, S. & Eckhart, W. C-terminal Src kinase associates with ligand-stimulated insulin-like growth factor-I receptor. J. Biol. Chem. 274, 5422\u20135428 (1999).","journal-title":"J. Biol. Chem."},{"key":"2729_CR233","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-023-02887-7","volume":"21","author":"X Zhang","year":"2023","unstructured":"Zhang, X. et al. Adipsin alleviates cardiac microvascular injury in diabetic cardiomyopathy through CSK-dependent signaling mechanism. BMC Med. 21, 197 (2023).","journal-title":"BMC Med."},{"key":"2729_CR234","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1210\/en.2003-0187","volume":"144","author":"H Sekimoto","year":"2003","unstructured":"Sekimoto, H. & Boney, C. M. C-Terminal Src kinase (CSK) modulates insulin-like growth factor-I signaling through Src in 3T3-L1 differentiation. Endocrinology 144, 2546\u20132552 (2003).","journal-title":"Endocrinology"},{"key":"2729_CR235","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1080\/21541248.2023.2212573","volume":"14","author":"S Hodder","year":"2023","unstructured":"Hodder, S., Fox, M., Binti, A. M., Mott, H. R. & Owen, D. ACKnowledging the role of the activated-Cdc42 associated kinase (ACK) in regulating protein stability in cancer. Small GTPases 14, 14 (2023).","journal-title":"Small GTPases"},{"key":"2729_CR236","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1091\/mbc.e10-07-0637","volume":"22","author":"H Shen","year":"2011","unstructured":"Shen, H. et al. Constitutive activated Cdc42-associated kinase (ACK) phosphorylation at arrested endocytic clathrin-coated pits of cells that lack dynamin. Mol. Biol. Cell 22, 493\u2013502 (2011).","journal-title":"Mol. Biol. Cell"},{"key":"2729_CR237","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1167\/iovs.63.11.25","volume":"63","author":"EI Yerlikaya","year":"2022","unstructured":"Yerlikaya, E. I. et al. Spleen tyrosine kinase contributes to m\u00fcller glial expression of proangiogenic cytokines in diabetes. Invest. Ophthalmol. Vis. Sci. 63, 25\u201325 (2022).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"2729_CR238","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1210\/me.2006-0354","volume":"21","author":"JW Xu","year":"2007","unstructured":"Xu, J. W., Morita, I., Ikeda, K., Miki, T. & Yamori, Y. C-Reactive protein suppresses insulin signaling in endothelial cells: role of spleen tyrosine kinase. Mol. Endocrinol. 21, 564\u2013573 (2007).","journal-title":"Mol. Endocrinol."},{"key":"2729_CR239","first-page":"2481","volume":"43","author":"S Li","year":"2019","unstructured":"Li, S. et al. Spleen tyrosine kinase\u2011induced JNK\u2011dependent NLRP3 activation is involved in diabetic cardiomyopathy. Int. J. Mol. Med. 43, 2481\u20132490 (2019).","journal-title":"Int. J. Mol. Med."},{"key":"2729_CR240","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1161\/ATVBAHA.120.314485","volume":"41","author":"MN Barrachina","year":"2021","unstructured":"Barrachina, M. N. et al. Phosphoproteomic analysis of platelets in severe obesity uncovers platelet reactivity and signaling pathways alterations. Arterioscler. Thromb. Vasc. Biol. 41, 478\u2013490 (2021).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2729_CR241","doi-asserted-by":"publisher","first-page":"16365","DOI":"10.1073\/pnas.1411086111","volume":"111","author":"R Keshet","year":"2014","unstructured":"Keshet, R. et al. C-Abl tyrosine kinase promotes adipocyte differentiation by targeting PPAR-gamma 2. Proc. Natl. Acad. Sci. USA 111, 16365\u201316370 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2729_CR242","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/XCE.0000000000000237","volume":"10","author":"R Menshawey","year":"2021","unstructured":"Menshawey, R., Menshawey, E., Alserr, A. H. K. & Abdelmassih, A. F. JAK out of the box; the rationale behind Janus kinase inhibitors in the COVID-19 setting, and their potential in obese and diabetic populations. Cardiovasc. Endocrinol. Metab. 10, 80\u201388 (2021).","journal-title":"Cardiovasc. Endocrinol. Metab."},{"key":"2729_CR243","doi-asserted-by":"publisher","first-page":"29301","DOI":"10.1074\/jbc.M115.670331","volume":"290","author":"J Mishra","year":"2015","unstructured":"Mishra, J., Verma, R. K., Alpini, G., Meng, F. & Kumar, N. Role of Janus kinase 3 in predisposition to obesity-associated metabolic syndrome. J. Biol. Chem. 290, 29301 (2015).","journal-title":"J. Biol. Chem."},{"key":"2729_CR244","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1038\/s41366-024-01584-6","volume":"48","author":"Z Ruppert","year":"2024","unstructured":"Ruppert, Z. et al. Characterization of obesity-related diseases and inflammation using single cell immunophenotyping in two different diet-induced obesity models. Int. J. Obes. 48, 1568\u20131576 (2024).","journal-title":"Int. J. Obes."},{"key":"2729_CR245","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1172\/JCI117495","volume":"94","author":"GS Hotamisligil","year":"1994","unstructured":"Hotamisligil, G. S., Budavari, A., Murray, D. & Spiegelman, B. M. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J. Clin. Invest. 94, 1543\u20131549 (1994).","journal-title":"J. Clin. Invest."},{"key":"2729_CR246","first-page":"4964","volume":"15","author":"B Umbayev","year":"2023","unstructured":"Umbayev, B. et al. The role of Cdc42 in the insulin and leptin pathways contributing to the development of age-related obesity. Nutr 15, 4964 (2023).","journal-title":"Nutr"},{"key":"2729_CR247","doi-asserted-by":"publisher","first-page":"706","DOI":"10.3390\/cells9030706","volume":"9","author":"JHM Yung","year":"2020","unstructured":"Yung, J. H. M. & Giacca, A. Role of c-Jun N-terminal Kinase (JNK) in Obesity and Type 2 Diabetes. Cells 9, 706 (2020).","journal-title":"Cells"},{"key":"2729_CR248","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.cmet.2011.09.011","volume":"14","author":"K Loh","year":"2011","unstructured":"Loh, K. et al. Elevated hypothalamic TCPTP in obesity contributes to cellular leptin resistance. Cell Metab. 14, 684\u2013699 (2011).","journal-title":"Cell Metab."},{"key":"2729_CR249","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1093\/lifemedi\/lnac044","volume":"1","author":"J Zhu","year":"2022","unstructured":"Zhu, J. et al. The natural product rotundic acid treats both aging and obesity by inhibiting PTP1B. Life Med. 1, 372\u2013386 (2022).","journal-title":"Life Med."},{"key":"2729_CR250","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.3390\/biomedicines10092139","volume":"10","author":"C Saint-Laurent","year":"2022","unstructured":"Saint-Laurent, C. et al. The tyrosine phosphatase SHP2: a new target for insulin resistance? Biomedicines 10, 2139\u20132139 (2022).","journal-title":"Biomedicines"},{"key":"2729_CR251","doi-asserted-by":"publisher","first-page":"5434","DOI":"10.1128\/MCB.24.12.5434-5446.2004","volume":"24","author":"K Ueki","year":"2004","unstructured":"Ueki, K., Kondo, T. & Kahn, C. R. Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol. Cell. Biol. 24, 5434\u20135446 (2004).","journal-title":"Mol. Cell. Biol."},{"key":"2729_CR252","doi-asserted-by":"publisher","first-page":"47944","DOI":"10.1074\/jbc.M104602200","volume":"276","author":"B Emanuelli","year":"2001","unstructured":"Emanuelli, B. et al. SOCS-3 inhibits insulin signaling and is up-regulated in response to tumor necrosis factor-\u03b1 in the adipose tissue of obese mice. J. Biol. Chem. 276, 47944\u201347949 (2001).","journal-title":"J. Biol. Chem."},{"key":"2729_CR253","doi-asserted-by":"publisher","first-page":"e47493","DOI":"10.1371\/journal.pone.0047493","volume":"7","author":"Z Yang","year":"2012","unstructured":"Yang, Z. et al. Regulation of insulin and leptin signaling by muscle suppressor of cytokine signaling 3 (SOCS3). PLoS ONE 7, e47493 (2012).","journal-title":"PLoS ONE"},{"key":"2729_CR254","doi-asserted-by":"publisher","first-page":"106840","DOI":"10.1016\/j.nbd.2025.106840","volume":"207","author":"O Al Massadi","year":"2025","unstructured":"Al Massadi, O. et al. PYK2 in the dorsal striatum of Huntington\u2019s disease R6\/2 mouse model. Neurobiol. Dis. 207, 106840 (2025).","journal-title":"Neurobiol. Dis."},{"key":"2729_CR255","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1093\/neuonc\/noy078","volume":"20","author":"NF Brown","year":"2018","unstructured":"Brown, N. F. et al. A study of the focal adhesion kinase inhibitor GSK2256098 in patients with recurrent glioblastoma with evaluation of tumor penetration of [11C]GSK2256098. Neuro Oncol. 20, 1634\u20131642 (2018).","journal-title":"Neuro Oncol."},{"key":"2729_CR256","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1080\/10790268.2017.1357104","volume":"41","author":"GJ Farkas","year":"2017","unstructured":"Farkas, G. J. & Gater, D. R. Neurogenic obesity and systemic inflammation following spinal cord injury: a review. J. Spinal Cord. Med. 41, 378 (2017).","journal-title":"J. Spinal Cord. Med."},{"key":"2729_CR257","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e15625","volume":"9","author":"M Li","year":"2023","unstructured":"Li, M. et al. Spleen tyrosine kinase (SYK) signals are implicated in cardio-cerebrovascular diseases. Heliyon 9, e15625 (2023).","journal-title":"Heliyon"},{"key":"2729_CR258","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15592","volume":"8","author":"A Giralt","year":"2017","unstructured":"Giralt, A. et al. Pyk2 modulates hippocampal excitatory synapses and contributes to cognitive deficits in a Huntington\u2019s disease model. Nat. Commun. 8, 15592 (2017).","journal-title":"Nat. Commun."},{"key":"2729_CR259","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3233\/JAD-2011-102025","volume":"25","author":"SD Schlatterer","year":"2011","unstructured":"Schlatterer, S. D., Tremblay, M. A., Acker, C. M. & Davies, P. Neuronal c-Abl overexpression leads to neuronal loss and neuroinflammation in the mouse forebrain. J. Alzheimers Dis. 25, 119\u2013137 (2011).","journal-title":"J. Alzheimers Dis."},{"key":"2729_CR260","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-9-117","volume":"9","author":"G Dhawan","year":"2012","unstructured":"Dhawan, G. & Combs, C. K. Inhibition of Src kinase activity attenuates amyloid associated microgliosis in a murine model of Alzheimer\u2019s disease. J. Neuroinflammation 9, 563 (2012).","journal-title":"J. Neuroinflammation"},{"key":"2729_CR261","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41374-021-00683-6","volume":"102","author":"A Hawez","year":"2021","unstructured":"Hawez, A. et al. c-Abl kinase regulates neutrophil extracellular trap formation and lung injury in abdominal sepsis. Lab. Investig. 102, 263\u2013271 (2021).","journal-title":"Lab. Investig."},{"key":"2729_CR262","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1523\/JNEUROSCI.1833-10.2011","volume":"31","author":"SZ Imam","year":"2011","unstructured":"Imam, S. Z. et al. Novel regulation of parkin function through c-Abl-mediated tyrosine phosphorylation: implications for Parkinson\u2019s disease. J. Neurosci. 31, 157\u2013163 (2011).","journal-title":"J. Neurosci."},{"key":"2729_CR263","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.470","volume":"7","author":"FL Pagan","year":"2019","unstructured":"Pagan, F. L. et al. Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson\u2019s disease. Pharmacol. Res. Perspect. 7, e00470 (2019).","journal-title":"Pharmacol. Res. Perspect."},{"key":"2729_CR264","first-page":"1221","volume":"19","author":"W Qian","year":"2010","unstructured":"Qian, W. et al. PP2A regulates Tau phosphorylation directly and also indirectly via activating GSK-3\u03b2. Disease 19, 1221\u20131229 (2010).","journal-title":"Disease"},{"key":"2729_CR265","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.nbd.2008.05.013","volume":"31","author":"XW Zhou","year":"2008","unstructured":"Zhou, X. W. et al. Tau hyperphosphorylation correlates with reduced methylation of protein phosphatase 2A. Neurobiol. Dis. 31, 386\u2013394 (2008).","journal-title":"Neurobiol. Dis."},{"key":"2729_CR266","first-page":"657","volume":"69","author":"LM Mao","year":"2017","unstructured":"Mao, L. M., Geosling, R., Penman, B. & Wang, J. Q. Local substrates of non-receptor tyrosine kinases at synaptic sites in neurons. Sheng Li Xue Bao 69, 657\u2013665 (2017).","journal-title":"Sheng Li Xue Bao"},{"key":"2729_CR267","doi-asserted-by":"publisher","first-page":"6100","DOI":"10.1523\/JNEUROSCI.0852-20.2020","volume":"40","author":"J Ghalayini","year":"2020","unstructured":"Ghalayini, J. Exploring the therapeutic potential of protein tyrosine phosphatase 1B in hAPP-J20 mouse model of Alzheimer\u2019s disease. J. Neurosci. 40, 6100\u20136102 (2020).","journal-title":"J. Neurosci."},{"key":"2729_CR268","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3389\/fnagi.2017.00007","volume":"9","author":"MNN Vieira","year":"2017","unstructured":"Vieira, M. N. N., Lyra E Silva, N. M., Ferreira, S. T. & De Felice, F. G. Protein tyrosine phosphatase 1B (PTP1B): a potential target for Alzheimer\u2019s therapy? Front. Aging Neurosci. 9, 7 (2017).","journal-title":"Front. Aging Neurosci."},{"key":"2729_CR269","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.3390\/genes15091204","volume":"15","author":"L Beckers","year":"2024","unstructured":"Beckers, L. et al. CD33 and SHP-1\/PTPN6 interaction in Alzheimer\u2019s disease. Genes 15, 1204 (2024).","journal-title":"Genes"},{"key":"2729_CR270","doi-asserted-by":"publisher","first-page":"7033","DOI":"10.3390\/ijms25137033","volume":"25","author":"D Ko\u0142odziej-Sobczak","year":"2024","unstructured":"Ko\u0142odziej-Sobczak, D., Sobczak, \u0141 & \u0141\u0105czkowski, K. Z. Protein tyrosine phosphatase 1B (PTP1B): a comprehensive review of its role in pathogenesis of human diseases. Int. J. Mol. Sci. 25, 7033\u20137033 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"2729_CR271","first-page":"1","volume":"2020","author":"CW Feng","year":"2020","unstructured":"Feng, C. W., Chen, N. F., Chan, T. F. & Chen, W. F. Therapeutic role of protein tyrosine phosphatase 1B in Parkinson\u2019s disease via antineuroinflammation and neuroprotection in Vitro and in Vivo. Park. Dis. 2020, 1\u201315 (2020).","journal-title":"Park. Dis."},{"key":"2729_CR272","first-page":"1251","volume":"22","author":"ZZ Chong","year":"2007","unstructured":"Chong, Z. Z. & Maiese, K. The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury. Histol. Histopathol. 22, 1251\u20131267 (2007).","journal-title":"Histol. Histopathol."},{"key":"2729_CR273","doi-asserted-by":"publisher","first-page":"109189","DOI":"10.1016\/j.abb.2022.109189","volume":"721","author":"S Kiratikanon","year":"2022","unstructured":"Kiratikanon, S., Chattipakorn, S. C., Chattipakorn, N. & Kumfu, S. The regulatory effects of PTPN6 on inflammatory process: reports from mice to men. Arch. Biochem. Biophys. 721, 109189 (2022).","journal-title":"Arch. Biochem. Biophys."},{"key":"2729_CR274","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.1007\/s10787-025-01796-w","volume":"33","author":"HM Al-Kuraishy","year":"2025","unstructured":"Al-Kuraishy, H. M. et al. Targeting the JAK\/STAT3\/SOCS signaling pathway in Alzheimer\u2019s disease. Inflammopharmacology 33, 2951\u20132962 (2025).","journal-title":"Inflammopharmacology"},{"key":"2729_CR275","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-021-01349-z","volume":"11","author":"NM Lyra e Silva","year":"2021","unstructured":"Lyra e Silva, N. M. et al. Pro-inflammatory interleukin-6 signaling links cognitive impairments and peripheral metabolic alterations in Alzheimer\u2019s disease. Transl. Psychiatry 11, 1\u201315 (2021).","journal-title":"Transl. Psychiatry"},{"key":"2729_CR276","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3389\/fnins.2018.00417","volume":"12","author":"L Cao","year":"2018","unstructured":"Cao, L., Wang, Z. & Wan, W. Suppressor of cytokine signaling 3: emerging role linking central insulin resistance and Alzheimer\u2019s disease. Front. Neurosci. 12, 417 (2018).","journal-title":"Front. Neurosci."},{"key":"2729_CR277","doi-asserted-by":"publisher","first-page":"110988","DOI":"10.1016\/j.brainresbull.2024.110988","volume":"213","author":"M Yan","year":"2024","unstructured":"Yan, M. et al. SOCS modulates JAK-STAT pathway as a novel target to mediate the occurrence of neuroinflammation: molecular details and treatment options. Brain Res. Bull. 213, 110988\u2013110988 (2024).","journal-title":"Brain Res. Bull."},{"key":"2729_CR278","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.neuroscience.2014.09.052","volume":"302","author":"DG Walker","year":"2015","unstructured":"Walker, D. G., Whetzel, A. M. & Lue, L. F. Expression of suppressor of cytokine signaling genes in human elderly and Alzheimer\u2019s disease brains and human microglia. Neuroscience 302, 121\u2013137 (2015).","journal-title":"Neuroscience"},{"key":"2729_CR279","doi-asserted-by":"publisher","first-page":"NS20220063","DOI":"10.1042\/NS20220063","volume":"7","author":"N Dzamko","year":"2023","unstructured":"Dzamko, N. Cytokine activity in Parkinson\u2019s disease. Neuronal Signal. 7, NS20220063 (2023).","journal-title":"Neuronal Signal."},{"key":"2729_CR280","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2147\/ITT.S240874","volume":"9","author":"A Lorenzo-Vizcaya","year":"2020","unstructured":"Lorenzo-Vizcaya, A., Fasano, S. & Isenberg, D. A. Bruton\u2019s tyrosine kinase inhibitors: a new therapeutic target for the treatment of SLE? Immunotargets Ther. 9, 105\u2013110 (2020).","journal-title":"Immunotargets Ther."},{"key":"2729_CR281","doi-asserted-by":"publisher","first-page":"6438","DOI":"10.1128\/MCB.00398-09","volume":"29","author":"C Brignatz","year":"2009","unstructured":"Brignatz, C. et al. Alternative splicing modulates autoinhibition and SH3 accessibility in the Src kinase Fyn. Mol. Cell. Biol. 29, 6438\u20136448 (2009).","journal-title":"Mol. Cell. Biol."},{"key":"2729_CR282","doi-asserted-by":"publisher","first-page":"4635","DOI":"10.4049\/jimmunol.179.7.4635","volume":"179","author":"A Filby","year":"2007","unstructured":"Filby, A. et al. Fyn regulates the duration of TCR engagement needed for commitment to effector function. J. Immunol. 179, 4635\u20134644 (2007).","journal-title":"J. Immunol."},{"key":"2729_CR283","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1111\/all.15261","volume":"77","author":"M Mendes-Bastos","year":"2022","unstructured":"Mendes-Bastos, M. et al. Bruton\u2019s tyrosine kinase inhibition\u2014an emerging therapeutic strategy in immune-mediated dermatological conditions. Allergy 77, 2355\u20132366 (2022).","journal-title":"Allergy"},{"key":"2729_CR284","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.3390\/jcm11102807","volume":"11","author":"E Robak","year":"2022","unstructured":"Robak, E. & Robak, T. Bruton\u2019s kinase inhibitors for the treatment of immunological diseases: current status and perspectives. J. Clin. Med. 11, 2807 (2022).","journal-title":"J. Clin. Med."},{"key":"2729_CR285","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00281-015-0541-1","volume":"38","author":"G Di Zenzo","year":"2016","unstructured":"Di Zenzo, G., Amber, K. T., Sayar, B. S., M\u00fcller, E. J. & Borradori, L. Immune response in pemphigus and beyond: progresses and emerging concepts. Semin. Immunopathol. 38, 57\u201374 (2016).","journal-title":"Semin. Immunopathol."},{"key":"2729_CR286","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/13543784.2023.2199919","volume":"32","author":"S Kubo","year":"2023","unstructured":"Kubo, S., Nakayamada, S. & Tanaka, Y. JAK inhibitors for rheumatoid arthritis. Expert Opin. Investig. Drugs 32, 333\u2013344 (2023).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"2729_CR287","doi-asserted-by":"publisher","first-page":"114929","DOI":"10.1016\/j.bcp.2022.114929","volume":"197","author":"G Kour","year":"2022","unstructured":"Kour, G. et al. Phytochemicals targeting JAK\/STAT pathway in the treatment of rheumatoid arthritis: Is there a future? Biochem Pharm. 197, 114929 (2022).","journal-title":"Biochem Pharm."},{"key":"2729_CR288","first-page":"1","volume":"29","author":"S Abdelhamid","year":"2021","unstructured":"Abdelhamid, S. & Huttunen, K. Orchestrated modulation of rheumatoid arthritis via crosstalking intracellular signaling pathways. Inflammopharmacology 29, 1\u201310 (2021).","journal-title":"Inflammopharmacology"},{"key":"2729_CR289","doi-asserted-by":"publisher","first-page":"512926","DOI":"10.1155\/2012\/512926","volume":"2012","author":"SE Byeon","year":"2012","unstructured":"Byeon, S. E. et al. The role of Src kinase in macrophage-mediated inflammatory responses. Mediat. Inflamm. 2012, 512926 (2012).","journal-title":"Mediat. Inflamm."},{"key":"2729_CR290","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","volume":"77","author":"S Banerjee","year":"2017","unstructured":"Banerjee, S., Biehl, A., Gadina, M., Hasni, S. & Schwartz, D. M. JAK\u2013STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs 77, 521\u2013546 (2017).","journal-title":"Drugs"},{"key":"2729_CR291","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","volume":"12","author":"DM Schwartz","year":"2016","unstructured":"Schwartz, D. M., Bonelli, M., Gadina, M. & O\u2019Shea, J. J. Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat. Rev. Rheumatol. 12, 25\u201336 (2016).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2729_CR292","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1161\/CIRCRESAHA.109.208199","volume":"105","author":"S Honsho","year":"2009","unstructured":"Honsho, S. et al. Pressure-mediated hypertrophy and mechanical stretch induces IL-1 release and subsequent IGF-1 generation to maintain compensative hypertrophy by affecting Akt and JNK pathways. Circ. Res. 105, 1149\u20131158 (2009).","journal-title":"Circ. Res."},{"key":"2729_CR293","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1189\/jlb.1009683","volume":"87","author":"J Chen","year":"2010","unstructured":"Chen, J. The Src\/PI3K\/Akt pathway may play a key role in the production of IL-17 in obesity. J. Leukoc. Biol. 87, 355\u2013355 (2010).","journal-title":"J. Leukoc. Biol."},{"key":"2729_CR294","doi-asserted-by":"publisher","first-page":"662223","DOI":"10.3389\/fimmu.2021.662223","volume":"12","author":"GE Ringheim","year":"2021","unstructured":"Ringheim, G. E., Wampole, M. & Oberoi, K. Bruton\u2019s tyrosine kinase (BTK) inhibitors and autoimmune diseases: making sense of BTK inhibitor specificity profiles and recent clinical trial successes and failures. Front. Immunol. 12, 662223 (2021).","journal-title":"Front. Immunol."},{"key":"2729_CR295","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41392-023-01331-9","volume":"8","author":"Q Ding","year":"2023","unstructured":"Ding, Q. et al. Signaling pathways in rheumatoid arthritis: implications for targeted therapy. Signal Transduct. Target. Ther. 8, 68 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2729_CR296","doi-asserted-by":"publisher","first-page":"909655","DOI":"10.3389\/fcell.2022.909655","volume":"10","author":"C Brunner","year":"2022","unstructured":"Brunner, C., Betzler, A. C., Brown, J. R., Andreotti, A. H. & Grassilli, E. Editorial: targeting bruton tyrosine kinase. Front. Cell Dev. Biol. 10, 909655 (2022).","journal-title":"Front. Cell Dev. Biol."},{"key":"2729_CR297","doi-asserted-by":"publisher","first-page":"1279155","DOI":"10.3389\/fimmu.2023.1279155","volume":"14","author":"E K\u00e1poszt\u00e1s","year":"2023","unstructured":"K\u00e1poszt\u00e1s, E. et al. The selective inhibition of the Syk tyrosine kinase ameliorates experimental autoimmune arthritis. Front. Immunol. 14, 1279155 (2023).","journal-title":"Front. Immunol."},{"key":"2729_CR298","doi-asserted-by":"publisher","first-page":"750466","DOI":"10.3389\/fimmu.2021.750466","volume":"12","author":"L Sandner","year":"2021","unstructured":"Sandner, L. et al. The tyrosine kinase Tec regulates effector Th17 differentiation, pathogenicity, and plasticity in T-cell-driven intestinal inflammation. Front. Immunol. 12, 750466 (2021).","journal-title":"Front. Immunol."},{"key":"2729_CR299","doi-asserted-by":"publisher","first-page":"375776","DOI":"10.3389\/fimmu.2018.01771","volume":"9","author":"L Potuckova","year":"2018","unstructured":"Potuckova, L., Draberova, L., Halova, I., Paulenda, T. & Draber, P. Positive and negative regulatory roles of C-terminal Src kinase (CSK) in FceRI-mediated mast cell activation, independent of the transmembrane adaptor PAG\/CSK-binding protein. Front. Immunol. 9, 375776 (2018).","journal-title":"Front. Immunol."},{"key":"2729_CR300","doi-asserted-by":"publisher","first-page":"3473","DOI":"10.2147\/DDDT.S348129","volume":"16","author":"E Carnero Contentti","year":"2022","unstructured":"Carnero Contentti, E. & Correale, J. Current perspectives: evidence to date on BTK inhibitors in the management of multiple sclerosis. Drug Des. Dev. Ther. 16, 3473\u20133490 (2022).","journal-title":"Drug Des. Dev. Ther."},{"key":"2729_CR301","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.3390\/cells10102560","volume":"10","author":"A Garc\u00eda-Merino","year":"2021","unstructured":"Garc\u00eda-Merino, A. Bruton\u2019s tyrosine kinase inhibitors: a new generation of promising agents for multiple sclerosis therapy. Cells 10, 2560 (2021).","journal-title":"Cells"},{"key":"2729_CR302","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.3390\/diagnostics12112789","volume":"12","author":"A Razaghi","year":"2022","unstructured":"Razaghi, A. et al. Proteomic analysis of pleural effusions from COVID-19 deceased patients: enhanced inflammatory markers. Diagnostics 12, 2789 (2022).","journal-title":"Diagnostics"},{"key":"2729_CR303","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s00011-020-01381-7","volume":"69","author":"BE Rumberger","year":"2020","unstructured":"Rumberger, B. E., Boarder, E. L., Owens, S. L. & Howell, M. D. Transcriptomic analysis of hidradenitis suppurativa skin suggests roles for multiple inflammatory pathways in disease pathogenesis. Inflamm. Res. 69, 967\u2013973 (2020).","journal-title":"Inflamm. Res."},{"key":"2729_CR304","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-023-02877-9","volume":"20","author":"B Nuesslein-Hildesheim","year":"2023","unstructured":"Nuesslein-Hildesheim, B. et al. Remibrutinib (LOU064) inhibits neuroinflammation driven by B cells and myeloid cells in preclinical models of multiple sclerosis. J. Neuroinflammation 20, 194 (2023).","journal-title":"J. Neuroinflammation"},{"key":"2729_CR305","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s11481-018-9783-8","volume":"13","author":"FA Jacobsen","year":"2018","unstructured":"Jacobsen, F. A. et al. A role for the non-receptor tyrosine kinase Abl2\/Arg in experimental neuroinflammation. J. Neuroimmune Pharmacol. 13, 265\u2013276 (2018).","journal-title":"J. Neuroimmune Pharmacol."},{"key":"2729_CR306","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1182\/blood-2018-08-871293","volume":"133","author":"L von Hoff","year":"2019","unstructured":"von Hoff, L. et al. Autocrine LTA signaling drives NF-\u03baB and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma. Blood 133, 1489\u20131494 (2019).","journal-title":"Blood"},{"key":"2729_CR307","doi-asserted-by":"publisher","first-page":"4302","DOI":"10.1074\/jbc.M116.773085","volume":"292","author":"LY Tang","year":"2017","unstructured":"Tang, L. Y. et al. Transforming growth factor-\u03b2 (TGF-\u03b2) directly activates the JAK1-STAT3 axis to induce hepatic fibrosis in coordination with the SMAD Pathway. J. Biol. Chem. 292, 4302\u20134312 (2017).","journal-title":"J. Biol. Chem."},{"key":"2729_CR308","first-page":"8463","volume":"27","author":"FHM Ali","year":"2023","unstructured":"Ali, F. H. M., Smatti, M. K., Elrayess, M. A., Thani, A. A. A. & Yassine, H. M. Role of genetics in eleven of the most common autoimmune diseases in the post genome-wide association studies era. Eur. Rev. Med. Pharmacol. Sci. 27, 8463\u20138485 (2023).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"2729_CR309","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/s41390-019-0436-2","volume":"86","author":"Q Zhu","year":"2019","unstructured":"Zhu, Q. et al. LCK rs10914542-G allele associates with type 1 diabetes in children via T cell hyporesponsiveness. Pediatr. Res. 86, 311\u2013315 (2019).","journal-title":"Pediatr. Res."},{"key":"2729_CR310","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1016\/j.biopha.2018.10.002","volume":"108","author":"P Kumar Singh","year":"2018","unstructured":"Kumar Singh, P., Kashyap, A. & Silakari, O. Exploration of the therapeutic aspects of Lck: A kinase target in inflammatory mediated pathological conditions. Biomed. Pharmacother. 108, 1565\u20131571 (2018).","journal-title":"Biomed. Pharmacother."},{"key":"2729_CR311","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1111\/febs.13709","volume":"283","author":"EN Gurzov","year":"2016","unstructured":"Gurzov, E. N., Stanley, W. J., Pappas, E. G., Thomas, H. E. & Gough, D. J. The JAK\/STAT pathway in obesity and diabetes. FEBS J. 283, 3002\u20133015 (2016).","journal-title":"FEBS J."},{"key":"2729_CR312","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05249-w","volume":"22","author":"J Matilainen","year":"2024","unstructured":"Matilainen, J. et al. Increased secretion of adipocyte-derived extracellular vesicles is associated with adipose tissue inflammation and the mobilization of excess lipid in human obesity. J. Transl. Med. 22, 623 (2024).","journal-title":"J. Transl. Med."},{"key":"2729_CR313","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.2337\/diabetes.53.9.2479","volume":"53","author":"JS Hulme","year":"2004","unstructured":"Hulme, J. S. et al. Association analysis of the lymphocyte-specific protein tyrosine kinase (LCK) gene in type 1 diabetes. Diabetes 53, 2479\u20132482 (2004).","journal-title":"Diabetes"},{"key":"2729_CR314","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.339","volume":"11","author":"W Gong","year":"2021","unstructured":"Gong, W. et al. CCL4-mediated targeting of spleen tyrosine kinase (Syk) inhibitor using nanoparticles alleviates inflammatory bowel disease. Clin. Transl. Med. 11, e339 (2021).","journal-title":"Clin. Transl. Med."},{"key":"2729_CR315","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s41422-020-0332-7","volume":"30","author":"D Zheng","year":"2020","unstructured":"Zheng, D., Liwinski, T. & Elinav, E. Interaction between microbiota and immunity in health and disease. Cell Res. 30, 492\u2013506 (2020).","journal-title":"Cell Res."},{"key":"2729_CR316","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.3390\/genes13122388","volume":"13","author":"S Jarmakiewicz-Czaja","year":"2022","unstructured":"Jarmakiewicz-Czaja, S., Zieli\u0144ska, M., Sokal, A. & Filip, R. Genetic and epigenetic etiology of inflammatory bowel disease: an update. Genes 13, 2388 (2022).","journal-title":"Genes"},{"key":"2729_CR317","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/j.omtn.2022.05.026","volume":"28","author":"M Stephens","year":"2022","unstructured":"Stephens, M., Keane, K., Roizes, S., Liao, S. & Weid, P. Y. Mincle-binding DNA aptamer demonstrates therapeutic potential in a model of inflammatory bowel disease. Mol. Ther. Nucleic Acids 28, 935\u2013947 (2022).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2729_CR318","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41575-020-0273-0","volume":"17","author":"N Salas","year":"2020","unstructured":"Salas, N. et al. JAK-STAT pathway targeting for the treatment of inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol. 17, 323\u2013337 (2020).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"2729_CR319","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1136\/gutjnl-2019-318448","volume":"68","author":"S Danese","year":"2019","unstructured":"Danese, S., Argollo, M., Le Berre, C. & Peyrin-Biroulet, L. JAK selectivity for inflammatory bowel disease treatment: does it clinically matter? Gut 68, 1893\u20131899 (2019).","journal-title":"Gut"},{"key":"2729_CR320","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2174\/1389200221666200310111409","volume":"21","author":"FS Macaluso","year":"2020","unstructured":"Macaluso, F. S. & Rodr\u00edguez-Lago, I. JAK inhibition as a therapeutic strategy for inflammatory bowel disease. Curr. Drug Metab. 21, 247\u2013255 (2020).","journal-title":"Curr. Drug Metab."},{"key":"2729_CR321","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/ibd\/izx031","volume":"24","author":"M Biagioli","year":"2018","unstructured":"Biagioli, M. et al. Genetic and pharmacological dissection of the role of spleen tyrosine kinase (Syk) in intestinal inflammation and immune dysfunction in inflammatory bowel diseases. Inflamm. Bowel Dis. 24, 123\u2013135 (2018).","journal-title":"Inflamm. Bowel Dis."},{"key":"2729_CR322","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.81577","volume":"12","author":"W Anderson","year":"2023","unstructured":"Anderson, W. et al. PTPN22 R620W gene editing in T cells enhances low-avidity TCR responses. eLife 12, e81577 (2023).","journal-title":"eLife"},{"key":"2729_CR323","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1097\/MIB.0000000000000297","volume":"21","author":"MR Spalinger","year":"2015","unstructured":"Spalinger, M. R., McCole, D. F., Rogler, G. & Scharl, M. Role of protein tyrosine phosphatases in regulating the immune system. Inflamm. Bowel Dis. 21, 645\u2013655 (2015).","journal-title":"Inflamm. Bowel Dis."},{"key":"2729_CR324","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3389\/fcimb.2015.00095","volume":"5","author":"RC Sharp","year":"2015","unstructured":"Sharp, R. C., Abdulrahim, M., Naser, E. S. & Naser, S. A. Genetic variations of PTPN2 and PTPN22: role in the pathogenesis of type 1 diabetes and crohn\u2019s disease. Front. Cell. Infect. Microbiol. 5, 95 (2015).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"2729_CR325","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/BOR.0000000000001008","volume":"36","author":"Y Qin","year":"2024","unstructured":"Qin, Y., Ma, J. & Vinuesa, C. G. Monogenic lupus: insights into disease pathogenesis and therapeutic opportunities. Curr. Opin. Rheumatol. 36, 191\u2013200 (2024).","journal-title":"Curr. Opin. Rheumatol."},{"key":"2729_CR326","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.3389\/fimmu.2019.02468","volume":"10","author":"C Niogret","year":"2019","unstructured":"Niogret, C., Birchmeier, W. & Guarda, G. SHP-2 in lymphocytes\u2019 cytokine and inhibitory receptor signaling. Front. Immunol. 10, 2468 (2019).","journal-title":"Front. Immunol."},{"key":"2729_CR327","doi-asserted-by":"publisher","first-page":"1393799","DOI":"10.3389\/fimmu.2024.1393799","volume":"15","author":"M Morelli","year":"2024","unstructured":"Morelli, M., Madonna, S. & Albanesi, C. SOCS1 and SOCS3 as key checkpoint molecules in the immune responses associated to skin inflammation and malignant transformation. Front. Immunol. 15, 1393799 (2024).","journal-title":"Front. Immunol."},{"key":"2729_CR328","doi-asserted-by":"publisher","first-page":"3715","DOI":"10.3390\/nu14183715","volume":"14","author":"P Kumar","year":"2022","unstructured":"Kumar, P., Mishra, J. & Kumar, N. Mechanistic Role of Jak3 in obesity-associated cognitive impairments. Nutrients 14, 3715 (2022).","journal-title":"Nutrients"},{"key":"2729_CR329","doi-asserted-by":"publisher","first-page":"151970","DOI":"10.1016\/j.bbrc.2025.151970","volume":"772","author":"Y Zhao","year":"2025","unstructured":"Zhao, Y. et al. Novel insight into the role of Src family kinases in hepatocellular carcinoma and therapeutic potential. Biochem. Biophys. Res. Commun. 772, 151970 (2025).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2729_CR330","doi-asserted-by":"publisher","first-page":"F145","DOI":"10.1152\/ajprenal.00092.2008","volume":"295","author":"J Xing","year":"2008","unstructured":"Xing, J., Zhang, Z., Mao, H., Schnellmann, R. G. & Zhuang, S. Src regulates cell cycle protein expression and renal epithelial cell proliferation via PI3K\/Akt signaling-dependent and -independent mechanisms. Am. J. Physiol. Ren. Physiol. 295, F145\u2013F152 (2008).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"2729_CR331","first-page":"1","volume":"6","author":"Y He","year":"2021","unstructured":"He, Y. et al. Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct. Target. Ther. 6, 1\u201317 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2729_CR332","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.7150\/ijms.49241","volume":"18","author":"Y Zhai","year":"2021","unstructured":"Zhai, Y. et al. Src-family Protein tyrosine kinases: a promising target for treating cardiovascular diseases. Int. J. Med. Sci. 18, 1216\u20131224 (2021).","journal-title":"Int. J. Med. Sci."},{"key":"2729_CR333","doi-asserted-by":"publisher","first-page":"4444","DOI":"10.3390\/ijms21124444","volume":"21","author":"C Matrone","year":"2020","unstructured":"Matrone, C., Petrillo, F., Nasso, R. & Ferretti, G. Fyn tyrosine kinase as harmonizing factor in neuronal functions and dysfunctions. Int. J. Mol. Sci. 21, 4444 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"2729_CR334","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.3390\/cells11213391","volume":"11","author":"OBJ Corneth","year":"2022","unstructured":"Corneth, O. B. J., Neys, S. F. H. & Hendriks, R. W. Aberrant B cell signaling in autoimmune diseases. Cells 11, 3391 (2022).","journal-title":"Cells"},{"key":"2729_CR335","doi-asserted-by":"publisher","first-page":"1339620","DOI":"10.3389\/fonc.2024.1339620","volume":"14","author":"VK Schmid","year":"2024","unstructured":"Schmid, V. K. & Hobeika, E. B cell receptor signaling and associated pathways in the pathogenesis of chronic lymphocytic leukemia. Front. Oncol. 14, 1339620 (2024).","journal-title":"Front. Oncol."},{"key":"2729_CR336","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1002\/art.39301","volume":"67","author":"KR Simpfendorfer","year":"2015","unstructured":"Simpfendorfer, K. R. et al. Autoimmune disease\u2013associated haplotypes of BLK exhibit lowered thresholds for B cell activation and expansion of Ig class-switched B cells. Arthritis Rheumatol. 67, 2866\u20132876 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"2729_CR337","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1038\/leu.2014.192","volume":"28","author":"N Petersen","year":"2014","unstructured":"Petersen, N. et al. B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL). Leukemia 28, 2109\u20132112 (2014).","journal-title":"Leukemia"},{"key":"2729_CR338","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.thromres.2014.11.009","volume":"135","author":"CP Loren","year":"2014","unstructured":"Loren, C. P. et al. The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear. Thromb. Res. 135, 155 (2014).","journal-title":"Thromb. Res."},{"key":"2729_CR339","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1093\/hmg\/dds220","volume":"21","author":"KR Simpfendorfer","year":"2012","unstructured":"Simpfendorfer, K. R. et al. The autoimmunity-associated BLK haplotype exhibits cis-regulatory effects on mRNA and protein expression that are prominently observed in B cells early in development. Hum. Mol. Genet. 21, 3918\u20133925 (2012).","journal-title":"Hum. Mol. Genet."},{"key":"2729_CR340","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.canlet.2021.08.038","volume":"524","author":"SF Yeung","year":"2022","unstructured":"Yeung, S. F., Zhou, Y., Zou, W., Chan, W. L. & Ching, Y. P. TEC kinase stabilizes PLK4 to promote liver cancer metastasis. Cancer Lett. 524, 70\u201381 (2022).","journal-title":"Cancer Lett."},{"key":"2729_CR341","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.ccr.2011.03.004","volume":"19","author":"OA Guryanova","year":"2011","unstructured":"Guryanova, O. A. et al. Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell 19, 498\u2013511 (2011).","journal-title":"Cancer Cell"},{"key":"2729_CR342","doi-asserted-by":"publisher","first-page":"1274209","DOI":"10.3389\/fphar.2024.1274209","volume":"15","author":"HH Hu","year":"2024","unstructured":"Hu, H. H. et al. Roles and inhibitors of FAK in cancer: current advances and future directions. Front. Pharmacol. 15, 1274209 (2024).","journal-title":"Front. Pharmacol."},{"key":"2729_CR343","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.3324\/haematol.2018.212027","volume":"105","author":"C Yu","year":"2020","unstructured":"Yu, C. et al. Phosphorylation of BECLIN-1 by BCR-ABL suppresses autophagy in chronic myeloid leukemia. Haematologica 105, 1285\u20131293 (2020).","journal-title":"Haematologica"},{"key":"2729_CR344","doi-asserted-by":"publisher","first-page":"13578","DOI":"10.1523\/JNEUROSCI.4390-09.2009","volume":"29","author":"B Spencer","year":"2009","unstructured":"Spencer, B. et al. Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in \u03b1-synuclein models of parkinson\u2019s and Lewy body diseases. J. Neurosci. 29, 13578\u201313588 (2009).","journal-title":"J. Neurosci."},{"key":"2729_CR345","first-page":"2190","volume":"118","author":"T Pickford","year":"2008","unstructured":"Pickford, T. et al. The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J. Clin. Invest. 118, 2190\u20132199 (2008).","journal-title":"J. Clin. Invest."},{"key":"2729_CR346","volume":"256","author":"BM Duggan","year":"2023","unstructured":"Duggan, B. M., Marko, D. M., Muzaffar, R., Chan, D. Y. & Schertzer, J. D. Kinase inhibitors for cancer alter metabolism, blood glucose, and insulin. J. Endocrinol. 256, e220212 (2023).","journal-title":"J. Endocrinol."},{"key":"2729_CR347","doi-asserted-by":"publisher","first-page":"183","DOI":"10.4103\/sjmms.sjmms_492_21","volume":"10","author":"M Althubiti","year":"2022","unstructured":"Althubiti, M. Tyrosine kinase targeting: a potential therapeutic strategy for diabetes. Saudi J. Med. Med. Sci. 10, 183 (2022).","journal-title":"Saudi J. Med. Med. Sci."},{"key":"2729_CR348","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1161\/CIRCULATIONAHA.120.049210","volume":"142","author":"L Xiao","year":"2020","unstructured":"Xiao, L. et al. Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal Src kinase. Circulation 142, 2443\u20132455 (2020).","journal-title":"Circulation"},{"key":"2729_CR349","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1200\/jco.2005.23.16_suppl.3145","volume":"23","author":"BC Goh","year":"2005","unstructured":"Goh, B. C. et al. Seliciclib (R-roscovitine) induces apoptosis in undifferentiated nasopharyngeal cancer (NPC) in vivo and in vitro. J. Clin. Oncol. 23, 3145\u20133145 (2005).","journal-title":"J. Clin. Oncol."},{"key":"2729_CR350","doi-asserted-by":"publisher","first-page":"5399","DOI":"10.1158\/0008-5472.CAN-05-0233","volume":"65","author":"DE MacCallum","year":"2005","unstructured":"MacCallum, D. E. et al. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II\u2013dependent transcription and down-regulation of Mcl-1. Cancer Res. 65, 5399\u20135407 (2005).","journal-title":"Cancer Res."},{"key":"2729_CR351","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1182\/blood-2005-01-0320","volume":"106","author":"N Raje","year":"2005","unstructured":"Raje, N. et al. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood 106, 1042\u20131047 (2005).","journal-title":"Blood"},{"key":"2729_CR352","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.7150\/ijbs.61229","volume":"17","author":"S Narayanan","year":"2021","unstructured":"Narayanan, S. et al. The spleen tyrosine kinase inhibitor, entospletinib (GS-9973) restores chemosensitivity in lung cancer cells by modulating ABCG2-mediated multidrug resistance. Int. J. Biol. Sci. 17, 2652 (2021).","journal-title":"Int. J. Biol. Sci."},{"key":"2729_CR353","doi-asserted-by":"publisher","first-page":"C902","DOI":"10.1152\/ajpcell.00296.2020","volume":"320","author":"TJ Zheng","year":"2021","unstructured":"Zheng, T. J. et al. Entospletinib. Am. J. Physiol. Cell Physiol. 320, C902\u2013C915 (2021).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"2729_CR354","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1080\/14756366.2021.1937143","volume":"36","author":"A Elkamhawy","year":"2021","unstructured":"Elkamhawy, A., Ali, E. M. H. & Lee, K. New horizons in drug discovery of lymphocyte-specific protein tyrosine kinase (Lck) inhibitors: a decade review (2011\u20132021) focussing on structure\u2013activity relationships (SAR) and docking insights. J. Enzym. Inhib. Med. Chem. 36, 1572\u20131600 (2021).","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"2729_CR355","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/bs.apcsb.2016.08.001","volume":"106","author":"JS Rawlings","year":"2017","unstructured":"Rawlings, J. S. Roles of SMC complexes during T lymphocyte development and function. Adv. Protein Chem. Struct. Biol. 106, 17\u201342 (2017).","journal-title":"Adv. Protein Chem. Struct. Biol."},{"key":"2729_CR356","unstructured":"Knox, C. et al. Entospletinib: uses, interactions, mechanism of action. DrugBank Online. https:\/\/go.drugbank.com\/drugs\/DB12121 (2025)."},{"key":"2729_CR357","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1002\/cncr.34780","volume":"129","author":"VH Duong","year":"2023","unstructured":"Duong, V. H. et al. Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial. Cancer 129, 2308\u20132320 (2023).","journal-title":"Cancer"},{"key":"2729_CR358","doi-asserted-by":"publisher","first-page":"749022","DOI":"10.3389\/fcvm.2021.749022","volume":"8","author":"R Duan","year":"2021","unstructured":"Duan, R. et al. Effects of the Btk-inhibitors remibrutinib (LOU064) and rilzabrutinib (PRN1008) with varying Btk selectivity over Tec on platelet aggregation and in vitro bleeding time. Front. Cardiovasc. Med. 8, 749022 (2021).","journal-title":"Front. Cardiovasc. Med."},{"key":"2729_CR359","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.4049\/jimmunol.2001130","volume":"206","author":"CL Langrish","year":"2021","unstructured":"Langrish, C. L. et al. Preclinical efficacy and anti-inflammatory mechanisms of action of the Bruton tyrosine kinase inhibitor rilzabrutinib for immune-mediated disease. J. Immunol. 206, 1454\u20131468 (2021).","journal-title":"J. Immunol."},{"key":"2729_CR360","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1080\/1750743X.2025.2545170","volume":"17","author":"DJ Kuter","year":"2025","unstructured":"Kuter, D. J. & Ghanima, W. Evaluating rilzabrutinib in the treatment of immune thrombocytopenia. Immunotherapy 17, 767\u2013782 (2025).","journal-title":"Immunotherapy"},{"key":"2729_CR361","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s40744-019-00182-7","volume":"7","author":"PH Schafer","year":"2019","unstructured":"Schafer, P. H. et al. Spebrutinib (CC-292) Affects markers of B cell activation, chemotaxis, and osteoclasts in patients with rheumatoid arthritis: results from a mechanistic study. Rheumatol. Ther. 7, 101\u2013119 (2019).","journal-title":"Rheumatol. Ther."},{"key":"2729_CR362","doi-asserted-by":"publisher","first-page":"333","DOI":"10.2147\/ITT.S288550","volume":"10","author":"LC Arneson","year":"2021","unstructured":"Arneson, L. C., Carroll, K. J. & Ruderman, E. M. Bruton\u2019s tyrosine kinase inhibitors for rheumatoid arthritis. Immunotargets Ther. 10, 333\u2013342 (2021).","journal-title":"Immunotargets Ther."},{"key":"2729_CR363","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.4049\/jimmunol.1800583","volume":"202","author":"P Haselmayer","year":"2019","unstructured":"Haselmayer, P. et al. Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models. J. Immunol. 202, 2888\u20132906 (2019).","journal-title":"J. Immunol."},{"key":"2729_CR364","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jnnp-2022-328799","volume":"94","author":"H Montalban","year":"2022","unstructured":"Montalban, H. et al. Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis. J. Neurol. Neurosurg. Psychiatry 94, 1\u20139 (2022).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"2729_CR365","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1080\/14796694.2025.2567834","volume":"21","author":"S Ibrahim","year":"2025","unstructured":"Ibrahim, S. et al. Pirtobrutinib in the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma. Future Oncol. 21, 3435\u20133445 (2025).","journal-title":"Future Oncol."},{"key":"2729_CR366","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/blood.2019001160","volume":"134","author":"CS Tam","year":"2019","unstructured":"Tam, C. S. et al. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood 134, 851\u2013859 (2019).","journal-title":"Blood"},{"key":"2729_CR367","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s11899-019-00512-0","volume":"14","author":"DA Bond","year":"2019","unstructured":"Bond, D. A. & Woyach, J. A. Targeting BTK in CLL: beyond Ibrutinib. Curr. Hematol. Malig. Rep. 14, 197\u2013205 (2019).","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"2729_CR368","doi-asserted-by":"publisher","first-page":"3216","DOI":"10.21037\/jgo-22-86","volume":"13","author":"KL Aung","year":"2022","unstructured":"Aung, K. L. et al. A phase II trial of GSK2256098 and trametinib in patients with advanced pancreatic ductal adenocarcinoma. J. Gastrointest. Oncol. 13, 3216\u20133226 (2022).","journal-title":"J. Gastrointest. Oncol."},{"key":"2729_CR369","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s00280-012-1904-0","volume":"70","author":"T Bartscht","year":"2012","unstructured":"Bartscht, T., Lehnert, H., Gieseler, F. & Ungefroren, H. The Src family kinase inhibitors PP2 and PP1 effectively block TGF-beta1-induced cell migration and invasion in both established and primary carcinoma cells. Cancer Chemother. Pharmacol. 70, 221\u2013230 (2012).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"2729_CR370","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0014-5793(03)00069-3","volume":"537","author":"R Karni","year":"2003","unstructured":"Karni, R. et al. The pp60c-Src inhibitor PP1 is non-competitive against ATP. FEBS Lett. 537, 47\u201352 (2003).","journal-title":"FEBS Lett."},{"key":"2729_CR371","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.124.013054","volume":"17","author":"A Xie","year":"2024","unstructured":"Xie, A. et al. c-Src is responsible for mitochondria-mediated arrhythmic risk in ischemic cardiomyopathy. Circ. Arrhythm. Electrophysiol. 17, e013054 (2024).","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"2729_CR372","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.ejmech.2017.05.006","volume":"136","author":"Z Cui","year":"2017","unstructured":"Cui, Z. et al. Design, synthesis and evaluation of azaacridine derivatives as dual-target EGFR and Src kinase inhibitors for antitumor treatment. Eur. J. Med. Chem. 136, 372\u2013381 (2017).","journal-title":"Eur. J. Med. Chem."},{"key":"2729_CR373","doi-asserted-by":"publisher","first-page":"3874","DOI":"10.2337\/db12-1010","volume":"62","author":"K Taniguchi","year":"2013","unstructured":"Taniguchi, K. et al. Inhibition of Src kinase blocks high glucose\u2013induced EGFR transactivation and collagen synthesis in mesangial cells and prevents diabetic nephropathy in mice. Diabetes 62, 3874\u20133886 (2013).","journal-title":"Diabetes"},{"key":"2729_CR374","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1164\/rccm.202010-3832OC","volume":"206","author":"F Ahangari","year":"2022","unstructured":"Ahangari, F. et al. Saracatinib, a selective Src kinase inhibitor, blocks fibrotic responses in preclinical models of pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 206, 1463\u20131479 (2022).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2729_CR375","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.95042","volume":"68","author":"E Williams","year":"2021","unstructured":"Williams, E. et al. Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva. JCI Insight 68, e95042 (2021).","journal-title":"JCI Insight"},{"key":"2729_CR376","unstructured":"National Jewish Health. Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04598919 (2024)."},{"key":"2729_CR377","doi-asserted-by":"publisher","first-page":"118234","DOI":"10.1016\/j.biopha.2025.118234","volume":"189","author":"T S Vasanthi","year":"2025","unstructured":"S Vasanthi, T. et al. Diet-incorporated saracatinib, a Src tyrosine kinase inhibitor, counteracts diisopropylfluorophosphate (DFP)-induced chronic neurotoxicity in the rat model. Biomed. Pharmacother. 189, 118234 (2025).","journal-title":"Biomed. Pharmacother."},{"key":"2729_CR378","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1182\/blood.V124.21.519.519","volume":"124","author":"JH Lipton","year":"2014","unstructured":"Lipton, J. H. et al. Epic: A Phase 3 Trial of ponatinib compared with imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CP-CML). Blood 124, 519 (2014).","journal-title":"Blood"},{"key":"2729_CR379","unstructured":"Incyte Biosciences International S\u00e0rl. Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03934372 (2025)."},{"key":"2729_CR380","doi-asserted-by":"publisher","first-page":"107615","DOI":"10.1016\/j.jbc.2024.107615","volume":"300","author":"S Dash","year":"2024","unstructured":"Dash, S. et al. The SRC family kinase inhibitor NXP900 demonstrates potent anti-tumor activity in squamous cell carcinomas. J. Biol. Chem. 300, 107615 (2024).","journal-title":"J. Biol. Chem."},{"key":"2729_CR381","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMoa2400858","volume":"391","author":"A Hochhaus","year":"2024","unstructured":"Hochhaus, A. et al. Asciminib in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. 391, 885\u2013898 (2024).","journal-title":"N. Engl. J. Med."},{"key":"2729_CR382","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","volume":"2","author":"AJ Parmentier","year":"2018","unstructured":"Parmentier, A. J. et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2, 23 (2018).","journal-title":"BMC Rheumatol."},{"key":"2729_CR383","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1080\/17460441.2025.2522890","volume":"20","author":"S Vieujean","year":"2025","unstructured":"Vieujean, S., Danese, S. & Peyrin-Biroulet, L. The preclinical discovery and development of upadacitinib for the treatment of Crohn\u2019s disease. Expert Opin. Drug Discov. 20, 951\u2013971 (2025).","journal-title":"Expert Opin. Drug Discov."},{"key":"2729_CR384","doi-asserted-by":"publisher","first-page":"e13688","DOI":"10.1111\/cts.13688","volume":"17","author":"MEF Mohamed","year":"2023","unstructured":"Mohamed, M. E. F., Bhatnagar, S., Parmentier, J. M., Nakasato, P. & Wung, P. Upadacitinib: mechanism of action, clinical, and translational science. Clin. Transl. Sci. 17, e13688 (2023).","journal-title":"Clin. Transl. Sci."},{"key":"2729_CR385","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1182\/bloodadvances.2019000954","volume":"4","author":"R Mullally","year":"2020","unstructured":"Mullally, R. et al. Fedratinib in myelofibrosis. Blood Adv. 4, 1792\u20131800 (2020).","journal-title":"Blood Adv."},{"key":"2729_CR386","doi-asserted-by":"publisher","first-page":"103649","DOI":"10.1016\/j.autrev.2024.103649","volume":"23","author":"C Ramakrishna","year":"2024","unstructured":"Ramakrishna, C., Mason, A. & Edwards, C. J. Tyrosine kinase 2 inhibitors in autoimmune diseases. Autoimmun. Rev. 23, 103649 (2024).","journal-title":"Autoimmun. Rev."},{"key":"2729_CR387","unstructured":"Padda, I. S., Bhatt, R., & Parmar, M. Upadacitinib (StatPearls Publishing, 2023)."},{"key":"2729_CR388","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41375-020-0954-2","volume":"35","author":"M Talpaz","year":"2020","unstructured":"Talpaz, M. & Kiladjian, J. J. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis. Leukemia 35, 1\u201317 (2020).","journal-title":"Leukemia"},{"key":"2729_CR389","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/cac2.12548","volume":"44","author":"M Zhao","year":"2024","unstructured":"Zhao, M. et al. Protein tyrosine phosphatases: emerging role in cancer therapy resistance. Cancer Commun. 44, 637\u2013653 (2024).","journal-title":"Cancer Commun."},{"key":"2729_CR390","doi-asserted-by":"publisher","first-page":"144740","DOI":"10.1016\/j.ijbiomac.2025.144740","volume":"316","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y. et al. PTPN2: advances and perspectives in cancer treatment potential and inhibitor research. Int. J. Biol. Macromol. 316, 144740\u2013144740 (2025).","journal-title":"Int. J. Biol. Macromol."},{"key":"2729_CR391","doi-asserted-by":"publisher","first-page":"4886","DOI":"10.1016\/j.apsb.2025.06.028","volume":"15","author":"Y Jang","year":"2025","unstructured":"Jang, Y. et al. Activatable PROTAC nanoassembly for photodynamic PTP1B proteolysis enhances glioblastoma immunotherapy. Acta Pharm. Sin. B 15, 4886\u20134899 (2025).","journal-title":"Acta Pharm. Sin. B"},{"key":"2729_CR392","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202300669","volume":"19","author":"J Miao","year":"2024","unstructured":"Miao, J. & Zhang, Z. Drugging protein tyrosine phosphatases through targeted protein degradation. ChemMedChem 19, e202300669 (2024).","journal-title":"ChemMedChem"},{"key":"2729_CR393","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41392-020-00454-7","volume":"5","author":"Y Jin","year":"2020","unstructured":"Jin, Y. et al. Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches. Signal Transduct. Target. Ther. 5, 293 (2020).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2729_CR394","volume":"64","author":"Y Zhu","year":"2025","unstructured":"Zhu, Y., Dai, Y. & Tian, Y. The peptide PROTAC modality: a new strategy for drug discovery. Med. Comm. 64, e70133 (2025).","journal-title":"Med. Comm."},{"key":"2729_CR395","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1177\/2472555217721142","volume":"22","author":"JS Lazo","year":"2017","unstructured":"Lazo, J. S., McQueeney, K. E. & Sharlow, E. R. New approaches to difficult drug targets: the phosphatase story. SLAS Discov. 22, 1071\u20131083 (2017).","journal-title":"SLAS Discov."},{"key":"2729_CR396","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.18632\/oncotarget.563","volume":"2","author":"T Yi","year":"2011","unstructured":"Yi, T. et al. Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: phase I trials to identify pharmacodynamic and clinical effects. Oncotarget 2, 1155\u20131164 (2011).","journal-title":"Oncotarget"},{"key":"2729_CR397","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1124\/molpharm.120.000131","volume":"98","author":"MP Czub","year":"2020","unstructured":"Czub, M. P. et al. Structure of the complex of an iminopyridinedione protein tyrosine phosphatase 4A3 phosphatase inhibitor with human serum albumin. Mol. Pharmacol. 98, 648\u2013657 (2020).","journal-title":"Mol. Pharmacol."},{"key":"2729_CR398","doi-asserted-by":"publisher","first-page":"8223","DOI":"10.18632\/oncotarget.23787","volume":"9","author":"ER McQueeney","year":"2017","unstructured":"McQueeney, E. R. et al. Targeting ovarian cancer and endothelium with an allosteric PTP4A3 phosphatase inhibitor. Oncotarget 9, 8223\u20138240 (2017).","journal-title":"Oncotarget"},{"key":"2729_CR399","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40495-018-0149-y","volume":"4","author":"R Tripathi","year":"2018","unstructured":"Tripathi, R., Liu, Z. & Plattner, R. Enabling tumor growth and progression: recent progress in unraveling the functions of ABL kinases in solid tumor cells. Curr. Pharmacol. Rep. 4, 367\u2013379 (2018).","journal-title":"Curr. Pharmacol. Rep."},{"key":"2729_CR400","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-021-00750-x","volume":"19","author":"MA Ortiz","year":"2021","unstructured":"Ortiz, M. A. et al. Src family kinases, adaptor proteins and the actin cytoskeleton in epithelial-to-mesenchymal transition. Cell Commun. Signal. 19, 67 (2021).","journal-title":"Cell Commun. Signal."},{"key":"2729_CR401","doi-asserted-by":"publisher","first-page":"110017","DOI":"10.1016\/j.biopha.2020.110017","volume":"125","author":"MM Ge","year":"2020","unstructured":"Ge, M. M. et al. Src-family protein tyrosine kinases: a promising target for treating chronic pain. Biomed. Pharmacother. 125, 110017\u2013110017 (2020).","journal-title":"Biomed. Pharmacother."},{"key":"2729_CR402","doi-asserted-by":"publisher","first-page":"R85","DOI":"10.1530\/REP-18-0440","volume":"157","author":"X Xiao","year":"2019","unstructured":"Xiao, X., Yang, Y., Mao, B., Cheng, C. Y. & Ni, Y. Emerging role for SRC family kinases in junction dynamics during spermatogenesis. Reproduction 157, R85\u2013R94 (2019).","journal-title":"Reproduction"},{"key":"2729_CR403","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1111\/j.1538-7836.2012.04814.x","volume":"10","author":"S S\u00e9verin","year":"2012","unstructured":"S\u00e9verin, S. et al. Distinct and overlapping functional roles of Src family kinases in mouse platelets. J. Thromb. Haemost. 10, 1631\u20131645 (2012).","journal-title":"J. Thromb. Haemost."},{"key":"2729_CR404","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1158\/1535-7163.MCT-22-0323","volume":"21","author":"RP Agashe","year":"2022","unstructured":"Agashe, R. P., Lippman, S. M. & Kurzrock, R. JAK: not just another kinase. Mol. Cancer Ther. 21, 1757\u20131764 (2022).","journal-title":"Mol. Cancer Ther."},{"key":"2729_CR405","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s00109-020-01958-z","volume":"98","author":"KS Lechner","year":"2020","unstructured":"Lechner, K. S., Neurath, M. F. & Weigmann, B. Role of the IL-2 inducible tyrosine kinase ITK and its inhibitors in disease pathogenesis. J. Mol. Med. 98, 1385\u20131395 (2020).","journal-title":"J. Mol. Med."},{"key":"2729_CR406","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.3389\/fimmu.2018.02027","volume":"9","author":"YR Roman-Garcia","year":"2018","unstructured":"Roman-Garcia, Y. R. et al. Distinct roles for Bruton\u2019s tyrosine kinase in B cell immune synapse formation. Front. Immunol. 9, 2027 (2018).","journal-title":"Front. Immunol."},{"key":"2729_CR407","doi-asserted-by":"publisher","first-page":"9154","DOI":"10.1111\/jcmm.15552","volume":"24","author":"T Chen","year":"2020","unstructured":"Chen, T. et al. Glycation of fibronectin inhibits VEGF-induced angiogenesis by uncoupling VEGF receptor-2-c-Src crosstalk. J. Cell. Mol. Med. 24, 9154\u20139164 (2020).","journal-title":"J. Cell. Mol. Med."},{"key":"2729_CR408","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1084\/jem.20070405","volume":"204","author":"EH Palacios","year":"2007","unstructured":"Palacios, E. H. & Weiss, A. Distinct roles for Syk and ZAP-70 during early thymocyte development. J. Exp. Med. 204, 1703\u20131715 (2007).","journal-title":"J. Exp. Med."},{"key":"2729_CR409","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-25622-3","volume":"12","author":"T Chan","year":"2021","unstructured":"Chan, T. et al. TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth. Nat. Commun. 12, 5337 (2021).","journal-title":"Nat. Commun."},{"key":"2729_CR410","doi-asserted-by":"publisher","first-page":"864995","DOI":"10.3389\/fimmu.2022.864995","volume":"13","author":"L Jing","year":"2022","unstructured":"Jing, L. et al. ACK1 contributes to the pathogenesis of inflammation and autoimmunity by promoting the activation of TLR signaling pathways. Front. Immunol. 13, 864995 (2022).","journal-title":"Front. Immunol."},{"key":"2729_CR411","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.tips.2024.11.006","volume":"46","author":"D Sridaran","year":"2025","unstructured":"Sridaran, D. & Mahajan, N. P. ACK1\/TNK2 kinase: molecular mechanisms and emerging cancer therapeutics. Trends Pharmacol. Sci. 46, 62\u201377 (2025).","journal-title":"Trends Pharmacol. Sci."},{"key":"2729_CR412","doi-asserted-by":"publisher","first-page":"110584","DOI":"10.1016\/j.celrep.2022.110584","volume":"39","author":"S Tavares","year":"2022","unstructured":"Tavares, S. et al. FER regulates endosomal recycling and is a predictor for adjuvant taxane benefit in breast cancer. Cell Rep. 39, 110584 (2022).","journal-title":"Cell Rep."},{"key":"2729_CR413","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1083\/jcb.201702184","volume":"217","author":"A Genna","year":"2017","unstructured":"Genna, A. et al. Pyk2 and FAK differentially regulate invadopodia formation and function in breast cancer cells. J. Cell Biol. 217, 375\u2013395 (2017).","journal-title":"J. Cell Biol."},{"key":"2729_CR414","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.expneurol.2018.05.020","volume":"307","author":"A Giralt","year":"2018","unstructured":"Giralt, A. et al. PTK2B\/Pyk2 overexpression improves a mouse model of Alzheimer\u2019s disease. Exp. Neurol. 307, 62\u201373 (2018).","journal-title":"Exp. Neurol."},{"key":"2729_CR415","doi-asserted-by":"publisher","first-page":"ar17","DOI":"10.1091\/mbc.E20-10-0640","volume":"32","author":"N Lukic","year":"2021","unstructured":"Lukic, N. et al. Pyk2 regulates cell-edge protrusion dynamics by interacting with Crk. Mol. Biol. Cell 32, ar17 (2021).","journal-title":"Mol. Biol. Cell"},{"key":"2729_CR416","doi-asserted-by":"publisher","first-page":"jcs261723","DOI":"10.1242\/jcs.261723","volume":"137","author":"DD Schlaepfer","year":"2024","unstructured":"Schlaepfer, D. D., Ojalill, M. & Stupack, D. G. Focal adhesion kinase signaling\u2014tumor vulnerabilities and clinical opportunities. J. Cell Sci. 137, jcs261723 (2024).","journal-title":"J. Cell Sci."},{"key":"2729_CR417","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-41116-1","volume":"9","author":"KS Thomas","year":"2019","unstructured":"Thomas, K. S. et al. Non-redundant functions of FAK and Pyk2 in intestinal epithelial repair. Sci. Rep. 9, 4497 (2019).","journal-title":"Sci. Rep."},{"key":"2729_CR418","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1074\/jbc.272.3.1856","volume":"272","author":"S Zrihan-Licht","year":"1997","unstructured":"Zrihan-Licht, S. et al. Association of csk-homologous kinase (CHK) (formerly MATK) with HER-2\/ErbB-2 in breast cancer cells. J. Biol. Chem. 272, 1856\u20131863 (1997).","journal-title":"J. Biol. Chem."},{"key":"2729_CR419","doi-asserted-by":"publisher","first-page":"12666","DOI":"10.1074\/jbc.M113.546481","volume":"289","author":"Q Yao","year":"2014","unstructured":"Yao, Q. et al. C-terminal Src kinase (Csk)-mediated phosphorylation of eukaryotic elongation factor 2 (eEF2) promotes proteolytic cleavage and nuclear translocation of eEF2. J. Biol. Chem. 289, 12666\u201312678 (2014).","journal-title":"J. Biol. Chem."},{"key":"2729_CR420","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","volume":"36","author":"JE Cortes","year":"2018","unstructured":"Cortes, J. E. et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J. Clin. Oncol. 36, 231\u2013237 (2018).","journal-title":"J. Clin. Oncol."},{"key":"2729_CR421","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood.2020009984","volume":"138","author":"D R\u00e9a","year":"2021","unstructured":"R\u00e9a, D. et al. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood 138, 2031 (2021).","journal-title":"Blood"},{"key":"2729_CR422","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1038\/s41375-024-02372-x","volume":"38","author":"C Gambacorti-Passerini","year":"2024","unstructured":"Gambacorti-Passerini, C. et al. Efficacy and safety of bosutinib in previously treated patients with chronic myeloid leukemia: final results from the BYOND trial. Leuk 38, 2162\u20132170 (2024).","journal-title":"Leuk"},{"key":"2729_CR423","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1042\/BJ20141165","volume":"465","author":"J Ozanne","year":"2015","unstructured":"Ozanne, J., Prescott, A. R. & Clark, K. The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting the salt-inducible kinases. Biochem. J. 465, 271 (2015).","journal-title":"Biochem. J."},{"key":"2729_CR424","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1016\/j.mayocp.2021.06.025","volume":"96","author":"O Salaami","year":"2021","unstructured":"Salaami, O. et al. Anti-diabetic effects of the senolytic agent dasatinib. Mayo Clin. Proc. 96, 3021 (2021).","journal-title":"Mayo Clin. Proc."},{"key":"2729_CR425","first-page":"10","volume":"127","author":"N Welsh","year":"2022","unstructured":"Welsh, N. Are off-target effects of imatinib the key to improving beta-cell function in diabetes? Ups. J. Med. Sci. 127, 10 (2022).","journal-title":"J. Med. Sci."},{"key":"2729_CR426","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/oncolo\/oyab040","volume":"27","author":"E Dianne Pulte","year":"2022","unstructured":"Dianne Pulte, E. et al. FDA approval summary: revised indication and dosing regimen for ponatinib based on the results of the OPTIC trial. Oncologist 27, 149 (2022).","journal-title":"Oncologist"},{"key":"2729_CR427","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41375-024-02159-0","volume":"38","author":"E Jabbour","year":"2024","unstructured":"Jabbour, E. et al. Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leuk 38, 475\u2013481 (2024).","journal-title":"Leuk"},{"key":"2729_CR428","unstructured":"Knox, C. et al. Ponatinib: uses, interactions, mechanism of action. DrugBank Online. https:\/\/go.drugbank.com\/drugs\/DB08901 (2025)."},{"key":"2729_CR429","unstructured":"Knox, C. et al. Asciminib: uses, interactions, mechanism of action. DrugBank Online. https:\/\/go.drugbank.com\/drugs\/DB12597 (2025)."},{"key":"2729_CR430","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1182\/blood-2020-140968","volume":"136","author":"P Schuld","year":"2020","unstructured":"Schuld, P. et al. Structural and biochemical studies confirming the mechanism of action of asciminib, an agent specifically targeting the ABL myristoyl pocket (STAMP). Blood 136, 34\u201335 (2020).","journal-title":"Blood"},{"key":"2729_CR431","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1158\/1535-7163.MCT-12-0146","volume":"11","author":"M Anbalagan","year":"2012","unstructured":"Anbalagan, M. et al. Peptidomimetic Src\/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER\/PR\/HER2-negative tumor xenografts. Mol. Cancer Ther. 11, 1936\u20131947 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"2729_CR432","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s10549-011-1513-3","volume":"132","author":"M Anbalagan","year":"2012","unstructured":"Anbalagan, M. et al. KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor \u03b1 positive breast cancer. Breast Cancer Res. Treat. 132, 391\u2013409 (2012).","journal-title":"Breast Cancer Res. Treat."},{"key":"2729_CR433","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s00280-013-2079-z","volume":"71","author":"ES Antonarakis","year":"2013","unstructured":"Antonarakis, E. S. et al. A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer. Cancer Chemother. Pharmacol. 71, 883\u2013892 (2013).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"2729_CR434","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3390\/medicina60020225","volume":"60","author":"F Li Pomi","year":"2024","unstructured":"Li Pomi, F. et al. Tirbanibulin 1% ointment for actinic keratosis: results from a real-life study. Medicina 60, 225 (2024).","journal-title":"Medicina"},{"key":"2729_CR435","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.abd.2019.10.004","volume":"94","author":"CPH Reinehr","year":"2019","unstructured":"Reinehr, C. P. H. & Bakos, R. M. Actinic keratoses: review of clinical, dermoscopic, and therapeutic aspects. An. Bras. Dermatol. 94, 637\u2013657 (2019).","journal-title":"An. Bras. Dermatol."},{"key":"2729_CR436","doi-asserted-by":"publisher","first-page":"e2022178","DOI":"10.5826\/dpc.1204a178","volume":"12","author":"S Sadeghi","year":"2022","unstructured":"Sadeghi, S. & Goodarzi, A. Various applications of tofacitinib and ruxolitinib (Janus kinase inhibitors) in dermatology and rheumatology: a review of current evidence and future perspective. Dermatol. Pract. Concept. 12, e2022178\u2013e2022178 (2022).","journal-title":"Dermatol. Pract. Concept."},{"key":"2729_CR437","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1016\/S2352-3026(17)30088-1","volume":"4","author":"CN Harrison","year":"2017","unstructured":"Harrison, C. N. et al. Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. Lancet Haematol. 4, e317\u2013e324 (2017).","journal-title":"Lancet Haematol."},{"key":"2729_CR438","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","volume":"76","author":"D Van Der Heijde","year":"2017","unstructured":"Van Der Heijde, D. et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann. Rheum. Dis. 76, 1340\u20131347 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"2729_CR439","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004291","volume":"10","author":"CJ Van De Laar","year":"2024","unstructured":"Van De Laar, C. J. et al. PERFECTRA: a pragmatic, multicentre, real-life study comparing treat-to-target strategies with baricitinib versus TNF inhibitors in patients with active rheumatoid arthritis after failure on csDMARDs. RMD Open 10, e004291 (2024).","journal-title":"RMD Open"},{"key":"2729_CR440","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.3390\/jcm12051734","volume":"12","author":"R Sanmart\u00ed","year":"2023","unstructured":"Sanmart\u00ed, R. & Corominas, H. Upadacitinib for patients with rheumatoid arthritis: a comprehensive review. J. Clin. Med. 12, 1734 (2023).","journal-title":"J. Clin. Med."},{"key":"2729_CR441","unstructured":"Knox, C. et al. DrugBank 6.0: the DrugBank Knowledgebase for 2024. Filgotinib: uses, interactions, mechanism of action. DrugBank Online. https:\/\/go.drugbank.com\/drugs\/DB14845 (2025)."},{"key":"2729_CR442","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s40744-019-00192-5","volume":"7","author":"JM Tarrant","year":"2020","unstructured":"Tarrant, J. M. et al. Filgotinib, a JAK1 inhibitor, modulates disease-related biomarkers in rheumatoid arthritis: results from two randomized, controlled phase 2b trials. Rheumatol. Ther. 7, 173 (2020).","journal-title":"Rheumatol. Ther."},{"key":"2729_CR443","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/cts.13435","volume":"16","author":"IM Catlett","year":"2022","unstructured":"Catlett, I. M. et al. First-in-human study of deucravacitinib: a selective, potent, allosteric small-molecule inhibitor of tyrosine kinase 2. Clin. Transl. Sci. 16, 151 (2022).","journal-title":"Clin. Transl. Sci."},{"key":"2729_CR444","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/bjh.16959","volume":"190","author":"R Boccia","year":"2020","unstructured":"Boccia, R. et al. Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia. Br. J. Haematol. 190, 933 (2020).","journal-title":"Br. J. Haematol."},{"key":"2729_CR445","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/ajh.25125","volume":"93","author":"J Bussel","year":"2018","unstructured":"Bussel, J. et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials. Am. J. Hematol. 93, 921 (2018).","journal-title":"Am. J. Hematol."},{"key":"2729_CR446","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s40267-018-0551-x","volume":"34","author":"K McKeage","year":"2018","unstructured":"McKeage, K. & Lyseng-Williamson, K. A. Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA. Drug. Ther. Persp. Drugs Ther. Perspect. 34, 451\u2013456 (2018).","journal-title":"Drug. Ther. Persp. Drugs Ther. Perspect."},{"key":"2729_CR447","doi-asserted-by":"publisher","first-page":"e0181178","DOI":"10.1371\/journal.pone.0181178","volume":"12","author":"MC Weir","year":"2017","unstructured":"Weir, M. C. et al. Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth. PLoS ONE 12, e0181178 (2017).","journal-title":"PLoS ONE"},{"key":"2729_CR448","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.15537\/smj.2025.46.10.20250385","volume":"46","author":"YA Kariri","year":"2025","unstructured":"Kariri, Y. A., Alqasmi, M. H. & Alqahtani, B. S. Phase IV clinical trials for the treatment of non-small cell lung carcinoma (NSCLC). Saudi Med. J. 46, 1119\u20131130 (2025).","journal-title":"Saudi Med. J."},{"key":"2729_CR449","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1182\/bloodadvances.2020002929","volume":"5","author":"AA Patel","year":"2021","unstructured":"Patel, A. A., Cahill, K., Saygin, C. & Odenike, O. Cedazuridine\/decitabine: from preclinical to clinical development in myeloid malignancies. Blood Adv. 5, 2264\u20132271 (2021).","journal-title":"Blood Adv."},{"key":"2729_CR450","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0788-y","volume":"17","author":"KS Siveen","year":"2018","unstructured":"Siveen, K. S. et al. Role of non receptor tyrosine kinases in hematological malignances and its targeting by natural products. Mol. Cancer 17, 31 (2018).","journal-title":"Mol. Cancer"},{"key":"2729_CR451","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1056\/NEJMoa1817073","volume":"381","author":"TD Shanafelt","year":"2019","unstructured":"Shanafelt, T. D. et al. Ibrutinib\u2013rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N. Engl. J. Med. 381, 432\u2013443 (2019).","journal-title":"N. Engl. J. Med."},{"key":"2729_CR452","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","volume":"391","author":"M Wang","year":"2017","unstructured":"Wang, M. et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet 391, 659\u2013667 (2017).","journal-title":"Lancet"},{"key":"2729_CR453","doi-asserted-by":"publisher","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","volume":"62","author":"Y Guo","year":"2019","unstructured":"Guo, Y. et al. Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton\u2019s tyrosine kinase. J. Med. Chem. 62, 7923\u20137940 (2019).","journal-title":"J. Med. Chem."},{"key":"2729_CR454","unstructured":"Knox, C. et al. Zanubrutinib: uses, interactions, mechanism of action. DrugBank Online. https:\/\/go.drugbank.com\/drugs\/DB15035 (2025)."},{"key":"2729_CR455","doi-asserted-by":"publisher","first-page":"e0282166","DOI":"10.1371\/journal.pone.0282166","volume":"18","author":"R Kozaki","year":"2023","unstructured":"Kozaki, R. et al. Investigation of the anti-tumor mechanism of tirabrutinib, a highly selective Bruton\u2019s tyrosine kinase inhibitor, by phosphoproteomics and transcriptomics. PLoS ONE 18, e0282166 (2023).","journal-title":"PLoS ONE"},{"key":"2729_CR456","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1358\/dot.2021.57.4.3264113","volume":"57","author":"W Munakata","year":"2021","unstructured":"Munakata, W. & Tobinai, K. Tirabrutinib hydrochloride for B-cell lymphomas. Drugs Today 57, 277\u2013289 (2021).","journal-title":"Drugs Today"},{"key":"2729_CR457","unstructured":"Knox, C. et al. Tirabrutinib: uses, interactions, mechanism of action. DrugBank Online. https:\/\/go.drugbank.com\/drugs\/DB15227 (2025)."},{"key":"2729_CR458","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.lungcan.2019.10.033","volume":"139","author":"DE Gerber","year":"2019","unstructured":"Gerber, D. E. et al. Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer. Lung Cancer 139, 60 (2019).","journal-title":"Lung Cancer"},{"key":"2729_CR459","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1158\/1535-7163.MCT-16-0366","volume":"15","author":"TA Marlowe","year":"2016","unstructured":"Marlowe, T. A., Lenzo, F. L., Figel, S. A., Grapes, A. T. & Cance, W. G. Oncogenic receptor tyrosine kinases directly phosphorylate focal adhesion kinase (FAK) as a resistance mechanism to FAK-kinase inhibitors. Mol. Cancer Ther. 15, 3028 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"2729_CR460","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","volume":"20","author":"P Cohen","year":"2021","unstructured":"Cohen, P., Cross, D. & J\u00e4nne, P. A. Kinase drug discovery 20 years after imatinib: progress and future directions. Nat. Rev. Drug Discov. 20, 551\u2013569 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2729_CR461","doi-asserted-by":"publisher","first-page":"18518","DOI":"10.1074\/jbc.M117.811174","volume":"292","author":"B Taskinen","year":"2017","unstructured":"Taskinen, B., Ferrada, E. & Fowler, D. M. Early emergence of negative regulation of the tyrosine kinase Src by the C-terminal Src kinase. J. Biol. Chem. 292, 18518\u201318529 (2017).","journal-title":"J. Biol. Chem."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02729-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02729-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02729-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T06:02:38Z","timestamp":1781589758000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02729-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":461,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2729"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02729-x","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"235"}}